https://www.medthority.com/clinical-trials/glomerulonephritis/a-study-to-evaluate-the-efficacy-and-safety-of-ro7434656-in-participants-with-primary-immunoglobulin-a-iga-nephropathy-at-high-risk-of-progression-imagination/2025-01-13T09:18:22+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/a-study-of-bion-1301-in-adults-with-iga-nephropathy/2025-01-13T09:18:23+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/a-study-of-qlg1074-combined-with-background-therapy-in-subjects-with-active-lupus-nephritis/2025-01-13T09:18:23+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/study-of-ravulizumab-in-immunoglobulin-a-nephropathy-igan-ican/2025-01-13T09:18:23+00:00weekly0.7https://www.medthority.com/clinical-trials/growth-hormone-deficiency/a-study-to-investigate-the-safety-and-efficacy-of-once-weekly-peg-somatropin-gensci004-in-children-with-growth-hormone-deficiency-escalate/2025-01-13T09:18:26+00:00weekly0.7https://www.medthority.com/clinical-trials/growth-hormone-deficiency/randomized-clinical-trial-of-two-different-initial-growth-hormone-doses-in-children/2025-01-13T09:18:26+00:00weekly0.7https://www.medthority.com/clinical-trials/growth-hormone-deficiency/phase-2-study-of-lum-201-in-children-with-growth-hormone-deficiency-oragrowth210-trial/2025-01-13T09:18:25+00:00weekly0.7https://www.medthority.com/clinical-trials/growth-hormone-deficiency/a-trial-to-investigate-long-term-efficacy-and-safety-of-lonapegsomatropin-in-adults-with-growth-hormone-deficiency/2025-01-13T09:18:26+00:00weekly0.7https://www.medthority.com/clinical-trials/growth-hormone-deficiency/a-research-study-in-children-with-a-low-level-of-hormone-to-grow.-treatment-is-somapacitan-once-a-week-compared-to-norditropin-once-a-day-real42025-01-13T09:18:26+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/talazoparib-enzalutamide-vs-enzalutamide-monotherapy-in-mcrpc-talapro-2/2025-01-13T09:19:04+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/a-study-to-learn-about-the-investigational-medicine-called-pf-06821497-mevrometostat-in-men-with-mcrpc-who-were-previously-treated-with-abiraterone-acetate-for-prostate-cancer-mevpro-1/2025-01-13T09:19:04+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/treatment-with-darolutamide---radiation-therapy-for-patients-with-a-castration-resistant-cancer-and-metastases-detected-by-functional-imaging-peace8/2025-01-13T09:19:03+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/a-study-to-assess-the-long-term-safety-and-efficacy-of-atb200at2221-in-adult-subjects-with-lopd/2025-01-13T09:18:59+00:00weekly0.7https://www.medthority.com/clinical-trials/cushings-syndrome/effect-of-vorinostat-on-acth-producing-pituitary-adenomas-in-cushings-disease/2025-05-05T14:20:30+00:00weekly0.7https://www.medthority.com/clinical-trials/heart-failure/a-study-to-test-whether-bi-690517-in-combination-with-empagliflozin-helps-people-with-heart-failure/2025-01-13T09:18:29+00:00weekly0.7https://www.medthority.com/clinical-trials/heart-failure/a-research-study-to-look-at-how-ziltivekimab-works-compared-to-placebo-in-people-with-heart-failure-and-inflammation-hermes/2025-01-13T09:18:29+00:00weekly0.7https://www.medthority.com/clinical-trials/heart-failure/phase-iii-study-investigating-heart-failure-and-cardiovascular-death-with-baxdrostat-in-combination-with-dapagliflozin-prevent-hf/2025-05-05T14:13:38+00:00weekly0.7https://www.medthority.com/clinical-trials/heart-failure/a-study-of-vericiguat-mk-1242-in-participants-with-chronic-heart-failure-with-reduced-ejection-fraction-hfref-mk-1242-035-victor/2025-01-13T09:18:28+00:00weekly0.7https://www.medthority.com/clinical-trials/cushings-syndrome/desmopressin-stimulation-test-performance-in-acth-dependent-cushing-syndrome/2025-01-31T09:30:34+00:00weekly0.7https://www.medthority.com/clinical-trials/cushings-syndrome/a-study-to-evaluate-the-safety-and-pk-of-crn04894-for-the-treatment-of-cushings-syndrome/2025-01-13T09:18:11+00:00weekly0.7https://www.medthority.com/clinical-trials/cushings-syndrome/fimepinostat-combination-hdac-and-pi3-kinase-inhibitor-tumor-directed-therapy-for-cushing-disease/2025-01-13T09:18:10+00:00weekly0.7https://www.medthority.com/clinical-trials/cushings-syndrome/spi-62-as-a-treatment-for-adrenocorticotropic-hormone-dependent-cushings-syndrome-rescue/2025-01-13T09:18:10+00:00weekly0.7https://www.medthority.com/clinical-trials/heart-failure/a-study-of-ponsegromab-in-people-with-heart-failure-garden-timi-74/2025-01-13T09:18:30+00:00weekly0.7https://www.medthority.com/clinical-trials/heart-failure/a-study-to-determine-the-efficacy-and-safety-of-finerenone-on-morbidity-and-mortality-among-hospitalized-heart-failure-patients-redefine-hf/2025-01-13T09:18:29+00:00weekly0.7https://www.medthority.com/clinical-trials/darzalex/a-study-to-evaluate-the-efficacy-and-safety-of-daratumumab-in-combination-with-cyclophosphamide-bortezomib-and-dexamethasone-cybord-compared-to-cybord-alone-in-newly-diagnosed-systemic-amyloid-light-chain-al-amyloidosis/2025-01-13T09:20:13+00:00weekly0.7https://www.medthority.com/clinical-trials/darzalex/daratumumab-maintenance-therapy-for-improving-survival-in-patients-with-light-chain-amyloidosis-emilia-trial/2025-01-13T09:20:13+00:00weekly0.7https://www.medthority.com/clinical-trials/darzalex/daratumumab-and-pomalidomide-in-previously-treated-patients-with-al-amyloidosis-darpal/2025-01-13T09:20:12+00:00weekly0.7https://www.medthority.com/clinical-trials/blenrep/a-study-of-belantamab-mafodotin-in-patients-with-relapsed-or-refractory-al-amyloidosis-emn27/2025-01-13T09:20:11+00:00weekly0.7https://www.medthority.com/clinical-trials/al-amyloidosis/a-study-to-evaluate-the-efficacy-and-safety-of-cael-101-in-patients-with-mayo-stage-iiia-al-amyloidosis/2025-01-13T09:17:40+00:00weekly0.7https://www.medthority.com/clinical-trials/al-amyloidosis/efficacy-of-18fflorbetaben-pet-for-diagnosis-of-cardiac-al-amyloidosis-cardiag/2025-01-13T09:17:40+00:00weekly0.7https://www.medthority.com/clinical-trials/al-amyloidosis/comparing-dara-vcd-chemotherapy-plus-stem-cell-transplant-to-dara-vcd-chemotherapy-alone-for-people-who-have-newly-diagnosed-al-amyloidosis/2025-01-13T09:17:40+00:00weekly0.7https://www.medthority.com/clinical-trials/al-amyloidosis/a-study-to-evaluate-the-efficacy-and-safety-of-birtamimab-in-mayo-stage-iv-patients-with-al-amyloidosis-affirm-al/2025-01-13T09:17:39+00:00weekly0.7https://www.medthority.com/clinical-trials/al-amyloidosis/study-of-the-safety-and-efficacy-of-sti-6129-in-patients-with-relapsed-or-refractory-systemic-al-amyloidosis/2025-01-13T09:17:39+00:00weekly0.7https://www.medthority.com/clinical-trials/al-amyloidosis/phase-12-study-of-zn-d5-for-the-treatment-of-relapsed-or-refractory-light-chain-al-amyloidosis/2025-01-13T09:17:39+00:00weekly0.7https://www.medthority.com/clinical-trials/ninlaro/ixazomib-maintenance-study-in-patients-with-al-amyloidosis/2025-01-13T09:20:41+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/safety-tolerability-and-efficacy-of-zilucoplan-in-subjects-with-generalized-myasthenia-gravis-raise/2025-01-13T09:18:51+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/an-open-label-study-to-evaluate-the-safety-tolerability-and-efficacy-of-subcutaneous-zilucoplan-in-participants-with-generalized-myasthenia-gravis-who-were-previously-receiving-intravenous-complement-component-5-inhibitors/2025-01-13T09:18:51+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/open-label-extension-of-zilucoplan-in-subjects-with-generalized-myasthenia-gravis-raise-xt/2025-01-13T09:18:51+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/study-of-alxn2050-in-adult-participants-with-generalized-myasthenia-gravis/2025-01-13T09:18:51+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/myasthenia-gravis-inebilizumab-trial-mint/2025-01-13T09:18:50+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/pyridostigmine-and-amifampridine-for-myasthenia-gravis-impact-mg/2025-01-13T09:18:50+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/a-study-of-nipocalimab-administered-to-adults-with-generalized-myasthenia-gravis/2025-01-13T09:18:50+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/evaluate-the-safety-of-hbm9161-hl161-subcutaneous-injection-in-patients-with-generalized-myasthenia-gravis/2025-01-13T09:18:50+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/safety-and-efficacy-of-alxn1720-in-adults-with-generalized-myasthenia-gravis/2025-01-13T09:18:49+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/phase-3-study-to-assess-the-efficacy-and-safety-of-batoclimab-as-induction-and-maintenance-therapy-in-adult-participants-with-generalized-myasthenia-gravis/2025-01-13T09:18:49+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/a-study-to-examine-the-efficacy-and-safety-of-pozelimab-and-cemdisiran-combination-therapy-in-adult-patients-with-symptomatic-generalized-myasthenia-gravis-nimble/2025-01-13T09:18:49+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/a-study-to-evaluate-efficacy-safety-pharmacokinetics-and-pharmacodynamics-of-satralizumab-in-patients-with-generalized-myasthenia-gravis/2025-01-13T09:18:49+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/study-of-telitacicept-in-generalized-myasthenia-gravis/2025-01-13T09:18:51+00:00weekly0.7https://www.medthority.com/clinical-trials/myasthenia-gravis/a-phase-3-open-label-crossover-study-to-evaluate-self-administration-of-rozanolixizumab-by-study-participants-with-generalized-myasthenia-gravis-gmg/2025-01-13T09:18:49+00:00weekly0.7https://www.medthority.com/clinical-trials/kesimpta/long-term-safety-tolerability-and-effectiveness-study-of-ofatumumab-in-patients-with-relapsing-ms-alithios/2025-01-13T09:20:37+00:00weekly0.7https://www.medthority.com/clinical-trials/kesimpta/efficacy-and-safety-of-ofatumumab-and-siponimod-compared-to-fingolimod-in-pediatric-patients-with-multiple-sclerosis-neos/2025-01-13T09:20:37+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/study-to-evaluate-the-efficacy-safety-and-tolerability-of-imu-838-in-patients-with-relapsing-multiple-sclerosis-ensure-1/2025-01-13T09:18:48+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/study-to-evaluate-the-efficacy-and-safety-of-fenebrutinib-compared-with-teriflunomide-in-relapsing-multiple-sclerosis-rms-fenhance-2/2025-01-13T09:18:48+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/masitinib-in-the-treatment-of-patients-with-primary-progressive-or-non-active-secondary-progressive-multiple-sclerosis-maxims/2025-01-13T09:18:48+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/best-available-therapy-versus-autologous-hematopoetic-stem-cell-transplant-for-multiple-sclerosis-beat-ms/2025-01-31T10:31:48+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/rituximab-versus-ocrelizumab-in-relapsing-remitting-multiple-sclerosis.-trio2025-01-13T09:18:47+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/efficacy-and-safety-of-remibrutinib-compared-to-teriflunomide-in-participants-with-relapsing-multiple-sclerosis/2025-01-13T09:18:47+00:00weekly0.7https://www.medthority.com/clinical-trials/multiple-sclerosis/nicotinamide-riboside-supplementation-in-progressive-multiple-sclerosis-norseman/2025-01-13T09:18:47+00:00weekly0.7https://www.medthority.com/clinical-trials/gilenya/safety-and-efficacy-of-fingolimod-in-pediatric-patients-with-multiple-sclerosis/2025-01-13T09:20:35+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/a-safety-extension-study-of-ontamalimab-in-participants-with-moderate-to-severe-ulcerative-colitis-or-crohns-disease-aida/2025-01-13T09:20:08+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/etrasimod-versus-placebo-for-the-treatment-of-moderately-active-ulcerative-colitis-gladiator-uc/2025-01-13T09:20:07+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/a-study-to-evaluate-etrasimod-treatment-in-adolescents-with-ulcerative-colitis/2025-01-13T09:20:07+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/abtect-1---abx464-treatment-evaluation-for-ulcerative-colitis-therapy--1/2025-01-13T09:20:07+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/study-for-participants-with-ulcerative-colitis-previously-enrolled-in-etrolizumab-phase-iiiii-studies-cottonwood/2025-01-13T09:20:07+00:00weekly0.7https://www.medthority.com/clinical-trials/tremfya/a-study-of-guselkumab-therapy-in-participants-with-moderately-to-severely-active-ulcerative-colitis-astro/2025-01-13T09:20:47+00:00weekly0.7https://www.medthority.com/clinical-trials/entyvio/a-study-of-vedolizumab-in-children-and-teenagers-with-moderate-to-severe-ulcerative-colitis-uc/2025-01-13T09:20:15+00:00weekly0.7https://www.medthority.com/clinical-trials/skyrizi/a-study-to-assess-the-efficacy-and-safety-of-risankizumab-in-participants-with-ulcerative-colitis/2025-01-13T09:20:45+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/parallel-double-dummy-superiority-study-levocetirizinepseudoephedrine-x-zina-for-allergic-rhinitis-in-brazil-alerzin/2025-01-13T09:17:44+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/efficacy-and-safety-of-lp-003-in-moderate-to-severe-seasonal-allergic-rhinitis-adult/2025-01-13T09:17:43+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/fixed-dose-combination-of-desloratadine--prednisolone-in-the-treat.-of-moderate---severe-allergic-rhinitis-in-children-despred2025-01-13T09:17:43+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/study-of-cm310-in-subjects-with-allergic-rhinitis/2025-01-13T09:17:42+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/a-study-of-il4r-monoclonal-antibody-in-patients-with-uncontrolled-seasonal-allergic-rhinitis/2025-01-13T09:17:42+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/safety-and-efficacy-of-efavaleukin-alfa-in-participants-with-moderately-to-severely-active-ulcerative-colitis/2025-01-13T09:20:07+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/study-evaluating-efficacy-and-safety-of-amiselimod-mt-1303-in-mild-to-moderate-ulcerative-colitis/2025-01-13T09:20:06+00:00weekly0.7https://www.medthority.com/clinical-trials/zeposia/a-study-investigating-oral-ozanimod-rpc1063-in-pediatric-participants-with-moderate-to-severe-active-ulcerative-colitis/2025-01-13T09:20:50+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/study-of-tilpisertib-fosmecarbil-in-participants-with-moderately-to-severely-active-ulcerative-colitis-palekona/2025-01-13T09:20:06+00:00weekly0.7https://www.medthority.com/clinical-trials/ulcerative-colitis/the-efficacy-and-safety-of-cobitolimod-in-participants-with-moderate-to-severe-active-left-sided-ulcerative-colitis-conclude/2025-01-13T09:20:06+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/eeg-mri-imaging-of-methylphenidate-effects-in-adult-adhd-and-attentional-symptoms-in-mood-disorders-imatem-tda/2025-01-13T09:17:38+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/phase-3-efficacy-and-safety-fixed-dose-study-in-pediatrics-6-17-with-adhd-using-ctx-1301/2025-01-13T09:17:37+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/a-trial-of-centanafadine-long-term-safety-in-children-and-adolescents-with-attention-deficithyperactivity-disorder-adhd/2025-01-13T09:17:37+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/development-of-virtual-reality-based-interventions-to-strengthen-cognitive-skillsets-related-to-attention-deficit-hyperactivity-disorder-adhd/2025-01-13T09:17:36+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/acute-effects-of-stimulant-medication-in-college-students-with-adhd/2025-01-13T09:17:36+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/efficacy-of-trigeminal-nerve-stimulation-for-adhd/2025-01-13T09:17:36+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/a-study-to-test-different-ways-to-measure-the-effect-of-atomoxetine-on-impulsive-behavior-in-young-adults-with-attention-deficit-hyperactivity-disorder-adhd/2025-01-13T09:17:35+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/neurocognitive-effects-of-non-invasive-near-infrared-light-stimulation/2025-01-13T09:17:35+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/clinical-efficacy-and-long-term-effects-of-transcranial-direct-current-stimulation-tdcs-in-children-with-attention-deficithyperactivity-disorder-adhd-stimadhd/2025-01-13T09:17:34+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/sublingual-immunotherapy-compared-to-intralymphatic-immunotherapy-with-concomitant-vitamin-d-a-randomised-placebo-controlled-study-ilit-vs-slit/2025-01-13T09:17:42+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/the-efficacy-of-rhinophototherapy-compared-to-intranasal-corticosteroids-on-the-nasal-mucosa/2025-01-13T09:17:41+00:00weekly0.7https://www.medthority.com/clinical-trials/allergic-rhinitis/effect-of-a-multistrain-probiotic-on-allergic-rhinitis-symptoms-and-gut-microbiota-composition-in-atopic-patients/2025-01-13T09:17:41+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-essential-hypertension-seric-eh/2025-01-13T09:18:33+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/evaluation-of-efficacy-and-safety-of-atb-1011atb-1012-co-administration-for-essential-hypertension-and-type-ii-diabetes/2025-01-13T09:18:32+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/efficacy-and-safety-of-olmesartan-associated-with-chlorthalidone-versus-benicar-hct-in-essential-hypertension-control/2025-01-13T09:18:32+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/a-study-to-evaluate-the-efficacy-and-safety-of-br1015-combination-therapy/2025-01-13T09:18:34+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/efficacy-and-safety-of-mexartan-potassium-tablets-azl-m-and-calcium-channel-blockers-ccb-in-the-treatment-of-adults-with-essential-hypertension-in-chinese-population-a-national-multicenter-prospective-observational-study/2025-01-13T09:18:33+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/study-to-evaluate-the-efficacy-and-safety-of-sph3127-in-patients-with-mild-moderate-essential-hypertension/2025-01-13T09:18:33+00:00weekly0.7https://www.medthority.com/clinical-trials/adhd/vitamin-d-as-a-therapeutic-adjunct-in-the-stimulant-treatment-of-adhd/2025-01-13T09:17:38+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/efficacy-and-safety-of-olmesartan-associated-with-chlorthalidone-in-essential-arterial-hypertension-control/2025-01-13T09:18:34+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/open-label-extension-study-to-assess-safety-efficacy-and-tolerability-of-lorundrostat-in-subjects-with-uncontrolled-hypertension/2025-01-13T09:18:34+00:00weekly0.7https://www.medthority.com/clinical-trials/hypertension/an-efficacy-safety-tolerability-and-dose-finding-study-of-xxb750-in-resistant-hypertension-patients/2025-01-13T09:18:34+00:00weekly0.7https://www.medthority.com/clinical-trials/sunosi/a-study-to-access-the-efficacy-and-safety-of-solriamfetol-in-subjects-with-adhd-focus/2025-01-13T09:20:46+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/monitoring-of-early-disease-progression-in-hereditary-transthyretin-amyloidosis-med-hattr/2025-01-13T09:20:05+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/a-research-study-to-look-at-how-a-new-medicine-called-nnc6019-0001-works-and-how-safe-it-is-for-people-who-have-heart-disease-due-to-transthyretin-ttr-amyloidosis/2025-01-13T09:20:05+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/an-extension-study-to-assess-long-term-safety-of-eplontersen-in-adults-with-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm/2025-01-13T09:20:05+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/amyloidosis-ttr-flow-reserve-evaluation-amytre/2025-01-13T09:20:05+00:00weekly0.7https://www.medthority.com/clinical-trials/amvuttra/helios-a-a-study-of-vutrisiran-aln-ttrsc02-in-patients-with-hereditary-transthyretin-amyloidosis-hattr-amyloidosis/2025-01-13T09:20:09+00:00weekly0.7https://www.medthority.com/clinical-trials/amvuttra/helios-b-a-study-to-evaluate-vutrisiran-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy/2025-01-13T09:20:09+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/analysis-of-lumbar-spine-stenosis-specimens-for-identification-of-transthyretin-cardiac-amyloidosis/2025-05-05T14:27:19+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/trammonittr-study-genetic-screening-of-an-at-risk-population-for-hattr-and-monitoring-of-ttr-positive-subjects-trammonittr/2025-01-13T09:20:04+00:00weekly0.7https://www.medthority.com/clinical-trials/transthyretin-amyloidosis/subclinical-transthyretin-cardiac-amyloidosis-in-v122i-ttr-carriers/2025-01-13T09:20:04+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-hepatic-porphyria/identification-of-acute-intermittent-porphyria-modifying-genes/2025-01-13T09:17:34+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-hepatic-porphyria/panhematin-for-prevention-of-acute-attacks-of-porphyria/2025-01-13T09:17:34+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-hepatic-porphyria/elevate-a-registry-of-patients-with-acute-hepatic-porphyria-ahp-elevate/2025-01-13T09:17:33+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-hepatic-porphyria/acute-porphyria-biomarkers-for-disease-activity/2025-01-13T09:17:33+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/tricaprilin-phase-3-ad-study/2025-01-13T09:17:51+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/masitinib-in-patients-with-mild-to-moderate-alzheimers-disease/2025-01-13T09:17:51+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/a-donanemab-ly3002813-prevention-study-in-participants-with-alzheimers-disease-trailblazer-alz-3/2025-01-13T09:17:50+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/evaluating-the-efficacy-and-safety-of-nilotinib-be-in-subjects-with-early-alzheimers-disease-nilead/2025-01-13T09:17:50+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/phase-3-double-blind-randomized-placebo-controlled-trial-to-evaluate-the-efficacy-and-safety-of-ar1001-in-participants-with-early-alzheimers-disease-polaris-ad/2025-01-13T09:17:50+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/a-pivotal-study-of-lipus-brain-in-patients-with-early-alzheimers-disease/2025-01-13T09:17:49+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/a-study-of-remternetug-ly3372993-in-participants-with-alzheimers-disease-trailrunner-alz-1/2025-01-13T09:17:49+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/a-study-to-verify-the-clinical-benefit-of-aducanumab-in-participants-with-early-alzheimers-disease-envision/2025-01-13T09:17:48+00:00weekly0.7https://www.medthority.com/clinical-trials/alzheimers-disease/ahead-3-45-study-a-study-to-evaluate-efficacy-and-safety-of-treatment-with-lecanemab-in-participants-with-preclinical-alzheimers-disease-and-elevated-amyloid-and-also-in-participants-with-early-preclinical-alzheimers-disease-and-intermediate-amyloid/2025-01-13T09:17:48+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/aav28-lsphgaa-actus-101-in-late-onset-pompe-disease/2025-01-13T09:19:00+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/evaluation-of-the-safety-and-efficacy-of-infantile-onset-pompe-disease-gene-therapy-drug/2025-01-31T09:34:06+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/a-study-to-evaluate-the-safety-efficacy-pk-pd-and-immunogenicity-of-cipaglucosidase-alfamiglustat-in-iopd-subjects-aged-0-to-18-rossella/2025-01-13T09:19:00+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/gene-transfer-study-in-patients-with-late-onset-pompe-disease-fortis/2025-01-13T09:19:00+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/zip-study-ol-study-of-safety-pk-efficacy-pd-immunogenicity-of-atb200at2221-in-pediatrics-aged-0-to--18-y.o.-wlopd2025-01-13T09:19:00+00:00weekly0.7https://www.medthority.com/clinical-trials/nexviadyme/clinical-study-for-treatment-naive-iopd-babies-to-evaluate-efficacy-and-safety-of-ert-with-avalglucosidase-alfa-baby-comet/2026-01-26T16:00:20+00:00weekly0.7https://www.medthority.com/clinical-trials/nexviadyme/a-study-to-assess-safety-and-efficacy-of-avalglucosidase-alfa-administered-every-other-week-in-pediatric-patients-with-infantile-onset-pompe-disease-previously-treated-with-alglucosidase-alfa-mini-comet/2026-01-26T16:01:13+00:00weekly0.7https://www.medthority.com/clinical-trials/pompe-disease/a-gene-transfer-study-for-late-onset-pompe-disease-resolute/2025-01-13T09:18:59+00:00weekly0.7https://www.medthority.com/clinical-trials/nexviadyme/avalglucosidase-alfa-french-post-trial-access-for-participants-with-pompe-disease-pta-avalglucosidase/2025-01-13T09:20:41+00:00weekly0.7https://www.medthority.com/clinical-trials/tezspire/efficacy-and-safety-of-tezepelumab-in-patients-with-eosinophilic-esophagitis-crossing/2025-05-05T14:12:54+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/dupilumab-in-eosinophilic-gastritis/2025-01-13T09:20:13+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/a-study-to-evaluate-the-efficacy-and-safety-of-cc-93538-in-adult-and-adolescent-participants-with-eosinophilic-esophagitis/2025-01-13T09:18:13+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/proton-pump-inhibitor-ppi-response-in-eosinophilic-esophagitis-assessed-by-transnasal-endoscopy-tne/2025-01-13T09:18:13+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-of-benralizumab-in-patients-with-eosinophilic-gastritis-andor-gastroenteritis-the-hudson-gi-study/2025-05-05T14:12:45+00:00weekly0.7https://www.medthority.com/clinical-trials/olumiant/a-study-of-baricitinib-ly3009104-in-participants-with-severe-or-very-severe-alopecia-areata-brave-aa1/2025-01-13T09:20:42+00:00weekly0.7https://www.medthority.com/clinical-trials/olumiant/a-study-of-baricitinib-ly3009104-in-children-from-6-years-to-less-than-18-years-of-age-with-alopecia-areata-brave-aa-peds/2025-01-13T09:20:42+00:00weekly0.7https://www.medthority.com/clinical-trials/olumiant/a-study-of-baricitinib-ly3009104-in-adults-with-severe-or-very-severe-alopecia-areata-brave-aa2/2025-01-13T09:20:42+00:00weekly0.7https://www.medthority.com/clinical-trials/alopecia-areata/study-of-daxdilimab-for-the-treatment-of-moderate-to-severe-alopecia-areata/2025-01-13T09:17:44+00:00weekly0.7https://www.medthority.com/clinical-trials/alopecia-areata/a-phase-2-durability-of-response-study-of-ctp-543-in-adult-patients-with-moderate-to-severe-alopecia-areata/2025-01-13T09:17:46+00:00weekly0.7https://www.medthority.com/clinical-trials/alopecia-areata/a-study-to-evaluate-efficacy-and-safety-of-deucravacitinib-in-participants-with-alopecia-areata/2025-01-13T09:17:46+00:00weekly0.7https://www.medthority.com/clinical-trials/alopecia-areata/study-to-evaluate-safety-and-efficacy-of-jaktinib-in-adults-with-alopecia-areata-aa/2025-01-13T09:17:45+00:00weekly0.7https://www.medthority.com/clinical-trials/alopecia-areata/safety-and-efficacy-of-oral-etrasimod-in-adult-participants-with-moderate-to-severe-alopecia-areata/2025-01-13T09:17:45+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/a-study-of-lasmiditan-ly573144-treatment-in-children-aged-6-to-17-with-migraine-pioneer-peds1/2025-01-13T09:18:45+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/a-study-to-evaluate-the-efficacy-and-safety-of-oral-zavegepant-in-migraine-prevention2/2025-01-13T09:18:44+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/long-term-extension-study-to-assess-safety-and-tolerability-of-oral-ubrogepant-tablets-for-the-acute-treatment-of-migraine-in-pediatric-participants-ages-6-17/2025-01-13T09:18:44+00:00weekly0.7https://www.medthority.com/clinical-trials/ajovy/a-study-to-test-if-fremanezumab-is-effective-in-preventing-migraine-in-children-and-adolescents/2025-01-13T09:20:09+00:00weekly0.7https://www.medthority.com/clinical-trials/ajovy/a-study-to-test-if-fremanezumab-is-effective-in-preventing-chronic-migraine-in-patients-6-to-17-years-of-age/2025-01-13T09:20:09+00:00weekly0.7https://www.medthority.com/clinical-trials/emgality/a-study-of-galcanezumab-ly2951742-in-participants-12-to-17-years-of-age-with-chronic-migraine-rebuild-2/2025-01-13T09:20:14+00:00weekly0.7https://www.medthority.com/clinical-trials/aimovig/efficacy-and-safety-of-erenumab-in-pediatric-subjects-with-chronic-migraine-oasiscm/2025-01-13T09:20:09+00:00weekly0.7https://www.medthority.com/clinical-trials/aimovig/efficacy-and-safety-of-erenumab-in-pediatric-subjects-with-episodic-migraine-oasisem/2025-01-13T09:20:08+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/a-pilot-clinical-trial-of-a-new-neuromodulation-device-for-acute-attacks-of-migraine-in-children-and-adolescents/2025-01-13T09:18:46+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/comparative-study-of-oral-atogepant-versus-oral-topiramate-to-assess-adverse-events-and-disease-activity-in-adult-participants-with-migraine-temple/2025-01-13T09:18:46+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/a-study-to-evaluate-the-efficacy-and-safety-of-oral-zavegepant-in-migraine-prevention/2025-01-13T09:18:46+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/mind-and-body-approaches-to-pain-reduction-in-youth-with-migraine/2025-01-13T09:18:46+00:00weekly0.7https://www.medthority.com/clinical-trials/migraine/efficacy-of-clorazepate-for-the-treatment-of-migraine-attack-in-the-emergency-room/2025-01-13T09:18:45+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/a-study-to-evaluate-the-efficacy-safety-pharmacokinetics-and-pharmacodynamic-effects-of-gdc-6599-in-patients-with-chronic-cough/2025-01-13T09:18:05+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/efficacy-of-sln-block-for-chronic-cough/2025-01-13T09:18:05+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/a-52-week-study-of-the-efficacy-and-safety-of-blu-5937-in-adults-with-refractory-chronic-cough-calm-1/2025-01-31T09:36:59+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/efficacy-of-two-doses-of-duloxetine-and-amitriptyline-in-subjects-with-refractory-chronic-cough-macs-1/2025-01-13T09:18:04+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/atp-and-p2x3-receptor-in-chronic-cough/2025-01-13T09:18:04+00:00weekly0.7https://www.medthority.com/clinical-trials/nucala/mepolizumab-for-the-treatment-of-chronic-cough-with-eosinophilic-airways-diseases-mucosa/2025-01-13T09:20:41+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/a-study-to-assess-the-efficacy-and-tolerance-of-hrs-2261-in-subjects-with-refractory-chronic-cough/2025-01-13T09:18:04+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-cough/cough-suppressive-therapy-in-patients-with-chronic-cough/2025-01-13T09:18:03+00:00weekly0.7https://www.medthority.com/clinical-trials/epidermolysis-bullosa/allogeneic-abcb5-positive-dermal-mesenchymal-stromal-cells-for-treatment-of-epidermolysis-bullosa-phase-iii/2025-01-13T09:18:16+00:00weekly0.7https://www.medthority.com/clinical-trials/epidermolysis-bullosa/eb-101-treatment-for-new-and-previously-treated-patients-with-recessive-dystrophic-epidermolysis-bullosa-rdeb/2025-01-13T09:18:15+00:00weekly0.7https://www.medthority.com/clinical-trials/epidermolysis-bullosa/injections-of-botulinic-toxin-in-plantar-lesions-of-localized-epidermolysis-bullosa-simplex-ebtox/2025-01-13T09:18:15+00:00weekly0.7https://www.medthority.com/clinical-trials/epidermolysis-bullosa/study-of-ptw-002-in-patients-with-dominant-or-recessive-dystrophic-epidermolysis-bullosa-due-to-mutations-in-exon-73-of-the-col7a1-gene/2025-01-13T09:18:15+00:00weekly0.7https://www.medthority.com/clinical-trials/epidermolysis-bullosa/a-study-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa-defi-rdeb/2025-01-13T09:18:15+00:00weekly0.7https://www.medthority.com/clinical-trials/epidermolysis-bullosa/open-label-pivotal-clinical-trial-to-confirm-efficacy-and-safety-of-autologous-grafts-containing-stem-cells-genetically-modified-for-epidermis-restoration-in-patients-with-junctional-epidermolysis-bullosa-hologene-5/2025-01-13T09:18:14+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/study-of-subcutaneous-epcoritamab-in-combination-with-intravenous-rituximab-and-oral-lenalidomide-r2-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-previously-untreated-follicular-lymphoma-epcorefl-2/2025-01-13T09:18:35+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/a-study-evaluating-efifcacy-and-safety-of-mosunetuzumab-in-combination-with-polatuzumab-vedotin-compared-to-rituximab-in-combination-with-gemcitabine-plus-oxaliplatin-in-participants-with-relapsed-or-refractory-aggressive-b-cell-non-hodgkins-lymphoma/2026-01-29T09:35:24+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/an-open-label-study-comparing-glofitamab-and-polatuzumab-vedotin--rituximab-cyclophosphamide-doxorubicin-and-prednisone-versus-pola-r-chp-in-previously-untreated-patients-with-large-b-cell-lymphoma/2025-01-13T09:18:37+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/study-to-compare-the-effectiveness-and-safety-of-golcadomide-plus-r-chop-vs-placebo-plus-r-chop-in-participants-with-previously-untreated-high-risk-large-b-cell-lymphoma-golseek-1/2025-01-13T09:18:36+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/a-trial-to-learn-if-odronextamab-combined-with-lenalidomide-is-safe-and-works-better-than-rituximab-combined-with-lenalidomide-in-participants-with-follicular-lymphoma-and-marginal-zone-lymphoma-olympia-5/2025-01-13T09:18:36+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/a-study-of-coformulated-favezelimabpembrolizumab-mk-4280a-versus-physicians-choice-chemotherapy-in-pd-l1-refractory-relapsed-or-refractory-classical-hodgkin-lymphoma-mk-4280a-008/2025-01-13T09:18:36+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/a-phase-iii-trial-comparing-tisagenlecleucel-to-standard-of-care-soc-in-adult-participants-with-rr-follicular-lymphoma-leda/2025-01-13T09:18:36+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/subcutaneous-epcoritamab-with-or-without-lenalidomide-as-first-line-therapy-for-diffuse-large-b-cell-lymphoma-epcore-dlbcl-3/2025-01-13T09:18:35+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/treatment-by-a-bispecific-cd3xcd20-antibody-for-relapserefractory-lymphomas-after-car-t-cells-therapy/2025-01-13T09:18:35+00:00weekly0.7https://www.medthority.com/clinical-trials/lymphoma/study-of-ibrutinib--cd20-antibody-and-venetoclax-in-patients-with-untreated-mantle-cell-lymphoma/2025-01-13T09:18:35+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/silicone-gel-vs.-estrogen-vaginal-cream-for-the-management-of-genitourinary-syndrome-of-menopause-vital-e2025-01-13T09:18:44+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/estetrol-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-in-postmenopausal-women-e4comfort-study-i/2025-01-13T09:18:43+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/a-study-to-learn-about-how-elinzanetant-works-and-how-safe-it-is-in-women-having-sleep-disturbances-associated-with-menopause-nirvana/2025-01-13T09:18:43+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/micronized-progesterone-versus-norethisterone-acetate-in-combination-with-estrogen-as-menopausal-hormone-therapy/2025-01-13T09:18:42+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/a-study-to-find-out-how-safe-long-term-treatment-with-fezolinetant-is-in-women-with-hot-flashes-going-through-menopause-skylight-4/2025-01-13T09:18:42+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/autologous-prp-infusion-may-restore-ovarian-function-and-may-promote-folliculogenesis-in-poi-patients-prp/2025-01-13T09:18:42+00:00weekly0.7https://www.medthority.com/clinical-trials/menopause/laser-therapy-for-treatment-of-genitourinary-syndrome-of-menopause-gsm-in-postmenopausal-women-laser_2022/2025-01-13T09:18:41+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/study-of-fluticasoneformoterolglycopyrronium-for-the-treatment-chronic-obstructive-pulmonary-disease-triplar/2025-01-13T09:18:08+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/a-study-to-evaluate-the-efficacy-and-safety-of-ensifentrine-for-24-weeks-in-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease/2025-01-13T09:18:08+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/a-study-evaluating-the-efficacy-of-budesonide-glycopyrronium-and-formoterol-fumarate-metered-dosed-inhaler-on-cardiopulmonary-outcomes-in-chronic-obstructive-pulmonary-disease-tharros/2025-05-05T14:09:58+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/a-study-comparing-efficacy-safety-and-tolerability-of-the-fixed-dose-triple-combination-chf-5993-with-the-fixed-dose-dual-combination-chf-1535-in-subjects-with-copd-triton/2025-01-13T09:18:08+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/a-study-to-evaluate-the-long-term-safety-of-astegolimab-in-participants-with-chronic-obstructive-pulmonary-disease-copd/2025-01-13T09:18:07+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/a-study-to-investigate-long-term-safety-and-tolerability-of-itepekimab-in-participants-with-copd-aerify-4/2025-01-13T09:18:07+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-obstructive-pulmonary-disease-copd/efficacy-and-safety-of-tozorakimab-in-symptomatic-chronic-obstructive-pulmonary-disease-with-a-history-of-exacerbations-miranda/2025-05-05T14:08:58+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/efficacy-and-safety-of-a-retinoid-in-the-treatment-of-severe-chronic-hand-eczema-handel/2025-01-13T09:18:27+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/topical-ruxolitinib-evaluation-in-chronic-hand-eczema/2025-01-13T09:18:27+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/treatment-of-chronic-hand-eczema-with-oral-roflumilast-hero/2025-01-13T09:18:27+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/efficacy-and-safety-of-dupilumab-chronic-hands-eczema-refractory-to-highly-potent-topical-corticosteroids-dupeczemain/2025-01-13T09:18:27+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/nedosiran-in-pediatric-patients-from-birth-to-11-years-of-age-with-ph-and-relatively-intact-renal-function-phyox8/2025-01-13T09:19:01+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/safety--efficacy-of-dcr-phxc-in-patients-with-ph12-and-esrd-phyox7/2025-01-13T09:19:01+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/a-study-to-evaluate-lumasiran-in-patients-with-advanced-primary-hyperoxaluria-type-1-illuminate-c2/2025-01-13T09:19:01+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/efficacy-safety-and-tolerability-of-abrocitinib-in-subjects-with-moderate-to-severe-chronic-hand-eczema-refractory-to-corticosteroid-therapy/2025-01-13T09:18:28+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/a-32-week-trial-to-evaluate-the-efficacy-and-safety-of-tralokinumab-in-subjects-with-moderate-to-severe-atopic-hand-eczema-who-are-candidates-for-systemic-therapy-adhand/2025-01-13T09:18:28+00:00weekly0.7https://www.medthority.com/clinical-trials/hand-and-foot-dermatitis/efficacy-and-safety-of-delgocitinib-cream-in-adolescents-12-17-years-of-age-with-moderate-to-severe-chronic-hand-eczema-delta-teen/2025-01-13T09:18:28+00:00weekly0.7https://www.medthority.com/clinical-trials/alpha-1-antitrypsin-deficiency/study-of-aro-aat-in-patients-with-alpha-1-antitrypsin-deficiency-associated-liver-disease-aatd/2025-01-13T09:17:47+00:00weekly0.7https://www.medthority.com/clinical-trials/alpha-1-antitrypsin-deficiency/safety-tolerability-and-pharmacodynamic-effect-of-aro-aat-sequoia/2025-01-13T09:17:47+00:00weekly0.7https://www.medthority.com/clinical-trials/alpha-1-antitrypsin-deficiency/a-study-of-belcesiran-in-patients-with-a1atd-associated-liver-disease-estrella/2025-01-13T09:17:47+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-study-to-compare-chemotherapy-alone-versus-chemotherapy-plus-nivolumab-or-nivolumab-and-bms-986205-followed-by-continued-therapy-after-surgery-with-nivolumab-or-nivolumab-and-bms-986205-in-participants-with-muscle-invasive-bladder-cancer/2025-01-13T09:18:03+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-study-of-nivolumab-plus-bempegaldesleukin-bempegnktr-214-vs-nivolumab-alone-vs-soc-in-participants-with-bladder-cancer-that-may-have-invaded-the-muscle-wall-of-the-bladder-and-who-cannot-get-cisplatin-a-type-of-medicine-given-to-treat-bladder-cancer/2025-01-13T09:18:03+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/catumaxomab-in-patients-with-non-muscle-invasive-bladder-cancer-who-have-failed-or-are-intolerant-to-bcg-vaccine/2025-01-13T09:17:58+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/efficacy-and-safety-of-pembrolizumab-mk-3475-in-combination-with-chemoradiotherapy-crt-versus-crt-alone-in-muscle-invasive-bladder-cancer-mibc-mk-3475-992keynote-992/2025-01-13T09:20:37+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-study-of-tar-200-in-combination-with-cetrelimab-tar-200-alone-or-cetrelimab-alone-in-participants-with-nmibc-unresponsive-to-intravesical-bacillus-calmette-guerin-who-are-ineligible-for-or-elected-not-to-undergo-radical-cystectomy-sunrise-1/2025-01-13T09:18:02+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-study-of-tar-200-in-combination-with-cetrelimab-versus-concurrent-chemoradiotherapy-in-participants-with-muscle-invasive-bladder-cancer-mibc-of-the-bladder-sunrise-2/2025-01-13T09:18:01+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-apl-1202-as-a-single-agent-oral-treatment-versus-intravesical-instillation-of-epirubicin-hydrochloride-in-naive-intermediate-risk-nmibc-patients-ascertain/2025-01-13T09:18:00+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/study-of-oral-infigratinib-for-the-adjuvant-treatment-of-subjects-with-invasive-urothelial-carcinoma-with-susceptible-fgfr3-genetic-alterations/2025-01-13T09:18:00+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/evaluating-safety-and-efficacy-of-verity-bcg-in-bcg-naive-patients-with-intermediate-and-high-risk-non-muscle-invasive-bladder-nmibc-ever/2025-01-13T09:17:59+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-study-of-enfortumab-vedotin-alone-or-with-other-therapies-for-treatment-of-urothelial-cancer-ev-103/2025-01-13T09:17:59+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/quilt-3.032-a-multicenter-clinical-trial-of-intravesical-bacillus-calmette-guerin-bcg-in-combination-with-alt-803-n-803-in-patients-with-bcg-unresponsive-high-grade-non-muscle-invasive-bladder-cancer2025-01-13T09:18:03+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/treatment-combination-of-durvalumab-tremelimumab-and-enfortumab-vedotin-or-durvalumab-and-enfortumab-vedotin-in-patients-with-muscle-invasive-bladder-cancer-ineligible-to-cisplatin-volga/2025-05-05T14:12:20+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-study-of-sasanlimab-in-people-with-non-muscle-invasive-bladder-cancer-crest/2025-01-13T09:18:02+00:00weekly0.7https://www.medthority.com/clinical-trials/tecentriq/a-study-of-atezolizumab-versus-placebo-as-adjuvant-therapy-in-patients-with-high-risk-muscle-invasive-bladder-cancer-who-are-ctdna-positive-following-cystectomy-imvigor011/2025-01-13T09:20:46+00:00weekly0.7https://www.medthority.com/clinical-trials/bladder-cancer/a-phase-3-single-arm-study-of-ugn-102-for-treatment-of-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-envision/2025-01-13T09:18:02+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/perioperative-enfortumab-vedotin-ev-plus-pembrolizumab-mk-3475-versus-neoadjuvant-chemotherapy-for-cisplatin-eligible-muscle-invasive-bladder-cancer-mibc-mk-3475-b15-keynote-b15--ev-304-keynote-b15/2025-01-13T09:20:38+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/efficacy-and-safety-of-pembrolizumab-mk-3475-in-combination-with-bacillus-calmette-guerin-bcg-in-high-risk-non-muscle-invasive-bladder-cancer-hr-nmibc-mk-3475-676keynote-676/2025-01-13T09:20:38+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/perioperative-pembrolizumab-mk-3475-plus-neoadjuvant-chemotherapy-versus-perioperative-placebo-plus-neoadjuvant-chemotherapy-for-cisplatin-eligible-muscle-invasive-bladder-cancer-mibc-mk-3475-866keynote-866-keynote-866/2025-01-13T09:20:38+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/perioperative-pembrolizumab-plus-cystectomy-or-perioperative-pembrolizumab-plus-ev-plus-cystectomy-vs-cystectomy-alone-in-participants-who-are-cisplatin-ineligible-or-decline-cisplatin-with-muscle-invasive-bladder-cancer-mk-3475-905keynote-905ev-303/2025-01-13T09:20:38+00:00weekly0.7https://www.medthority.com/clinical-trials/etripamil/safety-study-of-etripamil-nasal-spray-for-patients-with-paroxysmal-supraventricular-tachycardia.-node-3032021-09-24T08:13:39+00:00weekly0.7https://www.medthority.com/clinical-trials/etripamil/efficacy-and-safety-of-etripamil-for-the-termination-of-spontaneous-psvt.-node-301-part-1-and-part-2-the-rapid-study2021-09-24T08:13:39+00:00weekly0.7https://www.medthority.com/clinical-trials/luxturna/safety-and-efficacy-study-in-subjects-with-leber-congenital-amaurosis/2023-05-26T13:10:13+00:00weekly0.7https://www.medthority.com/clinical-trials/luxturna/a-patient-registry-study-for-patients-treated-with-voretigene-neparvovec-in-us/2023-05-26T13:09:45+00:00weekly0.7https://www.medthority.com/clinical-trials/luxturna/long-term-follow-up-study-in-subjects-who-received-voretigene-neparvovec-rzyl-aav2-hrpe65v2/2023-05-26T13:09:22+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/an-open-label-dose-escalation-and-double-masked-randomized-controlled-trial-evaluating-safety-and-tolerability-of-sepofarsen-in-children-8-years-of-age-with-lca10-caused-by-mutations-in-the-cep290-gene.-brighten2024-12-06T10:38:59+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/a-study-to-evaluate-efficacy-safety-tolerability-and-exposure-after-a-repeat-dose-of-sepofarsen-qr-110-in-lca10-illuminate-illuminate/2024-10-18T10:04:41+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/safety-and-efficacy-of-raav2tyf-grk1-rpgr-in-subjects-with-x-linked-retinitis-pigmentosa-caused-by-rpgr-mutations/2025-01-13T09:19:59+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/a-clinical-trial-evaluating-the-safety-and-efficacy-of-a-single-subretinal-injection-of-agtc-501-in-participants-with-x-linked-retinitis-pigmentosa-caused-by-rpgr-mutations/2025-01-13T09:19:59+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/gene-therapy-trial-for-the-treatment-of-x-linked-retinitis-pigmentosa-associated-with-variants-in-the-rpgr-gene/2025-01-13T09:19:59+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/a-first-in-human-proof-of-concept-study-of-cpk850-in-patients-with-rlbp1-retinitis-pigmentosa/2025-01-13T09:19:59+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/safety-and-efficacy-study-in-patients-with-retinitis-pigmentosa-due-to-mutations-in-pde6b-gene/2025-01-13T09:19:58+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/cb-prp-in-retinitis-pigmentosa-sicord/2025-01-13T09:19:58+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/investigation-of-therapeutic-efficacy-and-safety-of-umscs-for-the-management-of-retinitis-pigmentosa-rp/2025-01-13T09:19:58+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/study-of-subretinally-injected-sar439483-administered-in-patients-with-leber-congenital-amaurosis-caused-by-biallelic-mutations-in-gucy2d/2025-01-13T09:19:58+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/pde6a-gene-therapy-for-retinitis-pigmentosa-pigment/2025-01-13T09:19:58+00:00weekly0.7https://www.medthority.com/clinical-trials/retinal-dystrophies/safety-and-efficacy-of-npi-001-tablets-for-rp-associated-with-usher-syndrome-slo-rp/2025-01-13T09:19:57+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/effectiveness-and-safety-of-abp-938-in-patients-with-neovascular-age-related-macular-degeneration-neovascularwetamd/2025-01-13T09:18:38+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/a-study-of-the-efficacy-safety-and-pharmacokinetics-of-a-36-week-refill-regimen-for-the-port-delivery-system-with-ranibizumab-in-patients-with-neovascular-age-related-macular-degeneration-velodrome/2025-01-13T09:18:38+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/a-study-to-evaluate-the-long-term-safety-and-tolerability-of-faricimab-in-participants-with-neovascular-age-related-macular-degeneration-avonelle-x/2025-01-13T09:18:41+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/a-study-to-evaluate-the-efficacy-and-safety-of-faricimab-in-participants-with-neovascular-age-related-macular-degeneration-lucerne/2025-01-13T09:18:40+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/a-study-to-evaluate-the-efficacy-and-safety-of-faricimab-in-participants-with-neovascular-age-related-macular-degeneration-tenaya/2025-01-13T09:18:40+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/opt-302-with-aflibercept-in-neovascular-age-related-macular-degeneration-namd-coast/2025-01-13T09:18:40+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/opt-302-with-ranibizumab-in-neovascular-age-related-macular-degeneration-namd-shore/2025-01-13T09:18:39+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/horizon-a-phase-ii-study-to-evaluate-the-safety-and-efficacy-of-two-doses-of-gt005/2025-01-13T09:18:39+00:00weekly0.7https://www.medthority.com/clinical-trials/macular-degeneration/a-study-to-comparing-scd411-and-eylea-in-subjects-with-wet-age-related-macular-degeneration-amd/2025-01-13T09:18:39+00:00weekly0.7https://www.medthority.com/clinical-trials/beovu/efficacy-and-safety-of-brolucizumab-6mg-in-a-treat-and-extend-regimen-in-patients-with-neovascular-age-related-macular-degeneration-namd-with-prior-anti-vegf-exposure-peregrine/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/beovu/a-study-to-assess-the-effects-of-brolucizumab-in-adult-patients-with-neovascular-age-related-macular-degeneration-octopus/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/nucala/efficacy-and-safety-of-mepolizumab-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp-eosinophilic-chronic-rhinosinusitis-ecrs-merit/2024-12-06T10:01:00+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-study-of-benralizumab-in-patient-with-eosinophilic-chronic-rhinosinusitis-with-nasal-polyps-orchid/2025-05-05T14:24:34+00:00weekly0.7https://www.medthority.com/clinical-trials/nasal-polyposis/treatment-of-post-operative-sinonasal-polyposis-with-topical-furosemide/2025-01-13T09:18:52+00:00weekly0.7https://www.medthority.com/clinical-trials/nasal-polyposis/opn-375-efficacy-and-safety-in-adolescents-with-bilateral-nasal-polyps/2025-01-13T09:18:52+00:00weekly0.7https://www.medthority.com/clinical-trials/nasal-polyposis/a-study-assessing-the-efficacy-and-safety-of-cbp-201-in-adult-patients-with-chronic-rhinosinusitis-with-nasal-polyps/2025-01-13T09:18:52+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/dupilumab-severe-eosinophilic-chronic-sinusitis-without-nasal-polyposis/2024-12-06T10:44:07+00:00weekly0.7https://www.medthority.com/clinical-trials/xolair/a-clinical-trial-of-omalizumab-in-participants-with-chronic-rhinosinusitis-with-nasal-polyps-polyp-1/2021-09-24T08:22:01+00:00weekly0.7https://www.medthority.com/clinical-trials/xolair/a-clinical-trial-of-omalizumab-in-participants-with-chronic-rhinosinusitis-with-nasal-polyps-polyp-2/2021-09-24T08:22:01+00:00weekly0.7https://www.medthority.com/clinical-trials/spravato/a-long-term-safety-study-of-esketamine-nasal-spray-in-treatment-resistant-depression-sustain-3/2021-09-24T08:14:22+00:00weekly0.7https://www.medthority.com/clinical-trials/lynparza/efficacy-and-safety-study-of-cediranib-in-combination-with-olaparib-in-patients-with-recurrent-platinum-resistant-ovarian-cancer-concerto/2025-05-05T14:16:25+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/durvalumab-treatment-in-combination-with-chemotherapy-and-bevacizumab-followed-by-maintenance-durvalumab-bevacizumab-and-olaparib-treatment-in-advanced-ovarian-cancer-patients.-duo-o2025-05-05T14:16:50+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/a-study-of-weekly-tisotumab-vedotin-for-patients-with-platinum-resistant-ovarian-cancer-with-safety-run-in-innovatv-208/2025-01-13T09:18:56+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/apatinib-and-etoposide-capsule-versus-weekly-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer/2025-01-13T09:18:55+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/alpelisib-plus-olaparib-in-platinum-resistantrefractory-high-grade-serous-ovarian-cancer-with-no-germline-brca-mutation-detected/2026-01-29T09:32:50+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/a-study-to-evaluate-the-effectiveness-and-tolerability-of-a-second-maintenance-treatment-in-participants-with-ovarian-cancer-who-have-previously-received-polyadenosine-5diphosphoribose-poly-adp-ribose-polymerase-inhibitor-parpi-treatment.-duette2025-05-05T14:15:26+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/a-study-of-mirvetuximab-soravtansine-vs.-investigators-choice-of-chemotherapy-in-platinum-resistant-advanced-high-grade-epithelial-ovarian-primary-peritoneal-or-fallopian-tube-cancers-with-high-folate-receptor-alpha-expression-mirasol2025-01-13T09:18:57+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/oregovomab-plus-chemo-in-newly-diagnosed-patients-with-advanced-epithelial-ovarian-cancer-following-optimal-debulking-surgery-flora-5/2025-01-13T09:18:56+00:00weekly0.7https://www.medthority.com/clinical-trials/ovarian-cancer/study-of-chemotherapy-with-pembrolizumab-mk-3475-followed-by-maintenance-with-olaparib-mk-7339-for-the-first-line-treatment-of-women-with-brca-non-mutated-advanced-epithelial-ovarian-cancer-eoc-mk-7339-001keylynk-001engot-ov43gog-3036/2026-01-29T09:39:57+00:00weekly0.7https://www.medthority.com/clinical-trials/tecentriq/atezolizumab-with-bevacizumab-and-chemotherapy-vs-bevacizumab-and-chemotherapy-in-early-relapse-ovarian-cancer/2021-12-16T15:22:38+00:00weekly0.7https://www.medthority.com/clinical-trials/lynparza/a-study-to-examine-olaparib-maintenance-retreatment-in-patients-with-epithelial-ovarian-cancer.-oreo2025-05-05T14:14:30+00:00weekly0.7https://www.medthority.com/clinical-trials/lynparza/multicentre-study-of-olaparib-maintenance-monotherapy-in-platinum-sensitive-relapsed-non-gbrcam-ovarian-cancer-patients-opinion/2025-05-05T14:13:49+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/study-of-recombinant-human-b-lymphocyterc18-administered-subcutaneously-to-subjects-with-systemic-lupus-erythematosussle/2025-01-13T09:20:00+00:00weekly0.7https://www.medthority.com/clinical-trials/depression/efficacy-and-safety-of-mk-1942-when-added-to-stable-antidepressant-therapy-in-participants-with-treatment-resistant-depression-trd-mk-1942-006/2025-01-13T09:18:12+00:00weekly0.7https://www.medthority.com/clinical-trials/depression/elekt-d-electroconvulsive-therapy-ect-vs.-ketamine-in-patients-with-treatment-resistant-depression-trd-elekt-d2025-01-13T09:18:12+00:00weekly0.7https://www.medthority.com/clinical-trials/depression/the-safety-and-efficacy-of-psilocybin-in-participants-with-treatment-resistant-depression-p-trd/2025-01-13T09:18:12+00:00weekly0.7https://www.medthority.com/clinical-trials/depression/minocycline-as-adjunctive-treatment-for-treatment-resistant-depression-mindep2/2025-01-13T09:18:12+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/a-study-to-evaluate-the-efficacy-and-safety-of-dapirolizumab-pegol-in-study-participants-with-moderately-to-severely-active-systemic-lupus-erythematosus-phoenycs-go/2025-01-13T09:20:02+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/long-term-safety-of-anifrolumab-in-adult-subjects-with-active-systemic-lupus-erythematosus-tulip-sle-lte/2025-05-05T14:23:52+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/efficacy-and-safety-of-four-doses-of-cenerimod-compared-to-placebo-in-adult-subjects-with-active-systemic-lupus-erythematosus/2025-01-13T09:20:02+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/efficacy-and-safety-of-efavaleukin-alfa-in-subjects-with-active-systemic-lupus-erythematosus/2025-01-13T09:20:01+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/a-study-to-investigate-the-safety-and-efficacy-of-elsubrutinib-and-upadacitinib-given-alone-or-in-combination-in-participants-with-moderately-to-severely-active-systemic-lupus-erythematosus-sle/2025-01-13T09:20:01+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/treatment-of-systemic-lupus-erythematosus-sle-with-n-acetylcysteine-nac/2025-01-13T09:20:01+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/efficacy-and-safety-of-sirolimus-in-active-systemic-lupus-erythematosus-sirolupus/2025-01-13T09:20:00+00:00weekly0.7https://www.medthority.com/clinical-trials/systemic-lupus-erythematosus/long-term-safety-and-efficacy-study-of-bms-986165-in-participants-with-systemic-lupus-erythematosus/2025-01-13T09:20:00+00:00weekly0.7https://www.medthority.com/clinical-trials/benlysta/study-of-subcutaneous-sc-belimumab-in-pediatric-participants-with-systemic-lupus-erythematosus-sle/2024-12-06T09:59:51+00:00weekly0.7https://www.medthority.com/clinical-trials/benlysta/a-study-to-evaluate-the-efficacy-and-safety-of-belimumab-administered-in-combination-with-rituximab-to-adult-subjects-with-systemic-lupus-erythematosus-sle---bliss-believe/2024-12-06T10:00:07+00:00weekly0.7https://www.medthority.com/clinical-trials/spravato/a-long-term-comparison-of-esketamine-nasal-spray-versus-quetiapine-extended-release-escape-trd/2021-09-24T08:14:22+00:00weekly0.7https://www.medthority.com/clinical-trials/spravato/a-study-to-evaluate-the-efficacy-pharmacokinetics-safety-and-tolerability-of-flexible-doses-of-intranasal-esketamine-plus-an-oral-antidepressant-in-adult-participants-with-treatment-resistant-depression/2021-09-24T08:14:22+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/a-study-of-lumasiran-in-infants-and-young-children-with-primary-hyperoxaluria-type-1-illuminate-b/2025-01-13T09:19:03+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/a-study-to-evaluate-lumasiran-in-children-and-adults-with-primary-hyperoxaluria-type-1-illuminate-a/2025-01-13T09:19:03+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/a-study-to-evaluate-lumasiran-in-patients-with-advanced-primary-hyperoxaluria-type-1-illuminate-c/2025-01-13T09:19:03+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/study-to-evaluate-the-efficacy-and-safety-of-oxabact-oc5-in-primary-hyperoxaluria-patients-who-are-on-dialysis/2025-01-13T09:19:02+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/a-study-to-evaluate-the-efficacy-and-safety-of-oxabact-in-patients-with-primary-hyperoxaluria/2025-01-13T09:19:02+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/long-term-extension-study-in-patients-with-primary-hyperoxaluria-phyox3/2025-01-13T09:19:02+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/study-of-dcr-phxc-101-in-normal-healthy-volunteers-and-patients-with-primary-hyperoxaluria/2025-01-13T09:19:02+00:00weekly0.7https://www.medthority.com/clinical-trials/primary-hyperoxaluria-type-1/a-study-to-evaluate-dcr-phxc-in-children-and-adults-with-primary-hyperoxaluria-type-1-and-primary-hyperoxaluria-type-2-phyox2/2025-01-13T09:19:01+00:00weekly0.7https://www.medthority.com/clinical-trials/covid-19/trial-of-treatments-for-covid-19-in-hospitalized-adults-discovery/2025-01-13T09:18:10+00:00weekly0.7https://www.medthority.com/clinical-trials/covid-19/corimuno-19---tocilizumab-trial---toci-corimuno-toci/2025-01-13T09:18:10+00:00weekly0.7https://www.medthority.com/clinical-trials/covid-19/protective-role-of-inhaled-steroids-for-covid-19-infection-inhasco/2025-01-13T09:18:09+00:00weekly0.7https://www.medthority.com/clinical-trials/covid-19/abx464-in-treating-inflammation-and-preventing-acute-respiratory-failure-in-patients-with-covid-19-mir-age/2025-01-13T09:18:09+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/api-cat-study-for-apixaban-cancer-associated-thrombosis-api-cat/2022-03-17T14:09:58+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/select-d-anticoagulation-therapy-in-selected-cancer-patients-at-risk-of-recurrence-of-venous-thromboembolism/2022-03-17T14:10:20+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/rivaroxaban-in-the-treatment-of-venous-thromboembolism-vte-in-cancer-patients/2022-03-17T14:10:48+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/global-anticoagulant-registry-in-the-field--venous-thromboembolic-events-garfield-vte/2022-03-17T14:16:21+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/a-study-to-evaluate-the-efficacy-and-safety-of-rivaroxaban-venous-thromboembolism-vte-prophylaxis-in-ambulatory-cancer-participants/2022-03-17T14:16:00+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/apixaban-for-the-prevention-of-venous-thromboembolism-in-cancer-patients-avert/2022-03-17T14:15:35+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/cancer-venous-thromboembolism-vte/2022-03-17T14:14:59+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/apixaban-or-dalteparin-in-reducing-blood-clots-in-patients-with-cancer-related-venous-thromboembolism/2024-12-16T14:08:51+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/apixaban-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer-caravaggio/2022-03-17T14:14:08+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/a-non-interventional-study-on-xarelto-for-treatment-of-venous-thromboembolism-vte-and-prevention-of-recurrent-vte-in-patients-with-active-cancer-cosimo/2022-03-17T14:12:36+00:00weekly0.7https://www.medthority.com/clinical-trials/venous-thromboembolism-vte/cancer-associated-thrombosis-a-pilot-treatment-study-using-rivaroxaban-casta-diva/2022-03-17T14:11:57+00:00weekly0.7https://www.medthority.com/clinical-trials/zostavax/safety-and-effectiveness-of-live-zoster-vaccine-in-anti-tumor-necrosis-factor-tnf-users-verve-trial/2021-09-24T08:22:05+00:00weekly0.7https://www.medthority.com/clinical-trials/dovato/switch-study-to-evaluate-dolutegravir-plus-lamivudine-in-virologically-suppressed-human-immunodeficiency-virus-type-1-positive-adults-tango/2021-09-24T08:13:33+00:00weekly0.7https://www.medthority.com/clinical-trials/fostemsavir/attachment-inhibitor-comparison-in-heavily-treatment-experienced-patients/2021-09-24T08:13:41+00:00weekly0.7https://www.medthority.com/clinical-trials/lenacapavir/study-to-evaluate-the-safety-and-efficacy-of-lenacapavir-in-combination-with-an-optimized-background-regimen-in-heavily-treatment-experienced-participants-living-with-hiv-1-infection-with-multidrug-resistance-capella/2021-09-24T08:13:59+00:00weekly0.7https://www.medthority.com/clinical-trials/lenacapavir/study-to-evaluate-the-safety-and-efficacy-of-lenacapavir-in-combination-with-other-antiretroviral-agents-in-people-living-with-hiv-calibrate/2021-09-24T08:13:59+00:00weekly0.7https://www.medthority.com/clinical-trials/dovato/safety-and-efficacy-of-dolutegravirlamivudine-dtg3tc-in-therapy-naive-human-immunodeficiency-virus-1-hiv-1-infected-adolescents/2021-09-24T08:13:33+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/apol1-long-term-kidney-transplantation-outcomes-network-apollo/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/an-efficacy-and-safety-study-of-imlifidase-in-treatment-of-antibody-mediated-rejection-in-kidney-transplant-patients/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/cellular-immunotherapy-in-recipients-of-human-leukocyte-antigen-hla-mismatched-living-donor-kidney-transplants/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/artificial-kidney-initiation-in-kidney-injury-akiki/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/conversion-study-from-cyclosporine-to-fk506mr-based-immunosuppression-in-kidney-transplant-subjects-concerto/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/efficacy-and-safety-of-everolimus-with-enteric-coated-mycophenolate-sodium-ec-mps-in-a-cyclosporine-microemulsion-free-regimen-compared-to-standard-therapy-in-de-novo-renal-transplant-patients/2021-09-24T08:14:21+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/efficacy-and-safety-of-concentration-controlled-everolimus-to-eliminate-or-to-reduce-tacrolimus-compared-to-tacrolimus-in-de-novo-liver-transplant-recipients-rad/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/12-month-athena-study-everolimus-vs.-standard-regimen-in-de-novo-kidney-transplant-patients-athena2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/comparison-of-the-efficacy-and-safety-of-sirolimus-versus-everolimus-versus-mycophenolate-in-kidney-transplantation-sem/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/advancing-renal-transplant-efficacy-and-safety-outcomes-with-an-everolimus-based-regimen-transform/2021-09-24T08:14:21+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/everolimus-in-de-novo-kidney-transplant-recipients-neverwound/2021-09-24T08:14:21+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/ratg-versus-ratg-combined-with-intravenous-immunoglobulin-ivig-induction-immunosuppression-in-hla-incompatible-transplantation-inhibit-inhibit/2021-09-24T08:14:21+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/study-of-efficacy-safety-tolerability-pharmacokinetic-pk-and-pharmacodynamic-pd-of-an-anti-cd40-monoclonal-antibody-cfz533-in-kidney-transplant-recipients-cirrus-i/2021-09-24T08:14:21+00:00weekly0.7https://www.medthority.com/clinical-trials/bimzelx/a-study-to-test-the-efficacy-and-safety-of-bimekizumab-in-study-participants-with-moderate-to-severe-hidradenitis-suppurativa-be-heard-ii/2025-01-13T09:20:10+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/trial-to-determine-the-immunomodulatory-activity-of-ptm-001-in-patients-with-hidradenitis-suppurativa/2025-01-13T09:18:32+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/orismilast-for-the-treatment-of-mild-to-severe-hidradenitis-suppurativa-osiris/2025-01-13T09:18:32+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/a-study-of-ly3041658-in-adults-with-hidradenitis-suppurativa/2025-01-13T09:18:31+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/a-study-to-evaluate-the-efficacy-and-safety-of-imsidolimab-anb019-in-the-treatment-of-subjects-with-hidradenitis-suppurativa/2025-01-13T09:18:30+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/optimizing-intralesional-triamcinolone-dosing-for-hidradenitis-suppurativa/2025-01-13T09:18:30+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/treatment-of-hidradenitis-suppurativa-with-eth-755nm-alexandrite-laser/2025-01-13T09:18:31+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/study-of-efficacy-and-safety-of-investigational-treatment-in-patients-with-hidradenitis-suppurativa/2025-01-13T09:18:31+00:00weekly0.7https://www.medthority.com/clinical-trials/hidradenitis-suppurativa/a-study-of-bermekimab-for-the-treatment-of-participants-with-moderate-to-severe-hidradenitis-suppurativa-lyra/2025-01-13T09:18:31+00:00weekly0.7https://www.medthority.com/clinical-trials/bimzelx/a-study-to-evaluate-the-efficacy-and-safety-of-bimekizumab-in-study-participants-with-moderate-to-severe-hidradenitis-suppurativa-be-heard-i/2025-01-13T09:20:10+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/study-of-efficacy-and-safety-of-two-secukinumab-dose-regimens-in-subjects-with-moderate-to-severe-hidradenitis-suppurativa-hs-sunrise/2021-09-24T08:13:27+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/extension-study-to-assess-effects-of-non-interrupted-versus-interrupted-and-long-term-treatment-of-two-dose-regimes-of-secukinumab-in-subjects-with-hidradenitis-suppurativa/2021-09-24T08:13:27+00:00weekly0.7https://www.medthority.com/clinical-trials/forxiga/zibotentan-and-dapagliflozin-for-the-treatment-of-ckd-zenith-ckd-trial-zenith-ckd/2025-05-05T14:24:05+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-kidney-disease/clinical-trial-to-evaluate-safety-and-efficacy-of-us-apr2020-in-subjects-with-chronic-kidney-disease-stage-iv-ckd/2025-01-13T09:18:06+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-kidney-disease/resistant-starch-prebiotic-effects-in-chronic-kidney-disease-respeckd/2025-01-13T09:18:06+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-kidney-disease/a-study-to-evaluate-the-safety-and-efficacy-of-azd5718-in-participants-with-proteinuric-chronic-kidney-disease/2025-05-05T14:24:52+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-kidney-disease/a-study-to-test-the-effect-of-different-doses-of-bi-685509-on-kidney-function-in-people-with-chronic-kidney-disease-who-do-not-have-diabetes2/2025-01-13T09:18:05+00:00weekly0.7https://www.medthority.com/clinical-trials/esbriet/trial-of-pirfenidone-to-prevent-progression-in-chronic-kidney-disease-top-ckd/2021-09-24T08:13:39+00:00weekly0.7https://www.medthority.com/clinical-trials/forxiga/dapagliflozin-in-non-diabetic-stage-iv-ckd-adapt/2021-09-24T08:13:41+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-kidney-disease/a-study-to-test-the-effect-of-different-doses-of-bi-685509-on-kidney-function-in-people-with-chronic-kidney-disease-who-do-not-have-diabetes/2025-01-13T09:18:07+00:00weekly0.7https://www.medthority.com/clinical-trials/chronic-kidney-disease/a-trial-of-bardoxolone-methyl-in-patients-with-ckd-at-risk-of-rapid-progression-merlin/2025-01-13T09:18:06+00:00weekly0.7https://www.medthority.com/clinical-trials/retsevmo/a-study-of-loxo-292-in-participants-with-advanced-solid-tumors-ret-fusion-positive-solid-tumors-and-medullary-thyroid-cancer-libretto-001/2025-05-05T14:28:06+00:00weekly0.7https://www.medthority.com/clinical-trials/retsevmo/a-study-of-selpercatinib-ly3527723-in-participants-with-advanced-solid-tumors-including-ret-fusion-positive-solid-tumors-medullary-thyroid-cancer-and-other-tumors-with-ret-activation-libretto-321/2025-05-05T14:28:28+00:00weekly0.7https://www.medthority.com/clinical-trials/retsevmo/a-study-of-selpercatinib-ly3527723-in-participants-with-ret-mutant-medullary-thyroid-cancer-libretto-531/2025-05-05T14:28:47+00:00weekly0.7https://www.medthority.com/clinical-trials/retsevmo/selpercatinib-before-surgery-for-the-treatment-of-ret-altered-thyroid-cancer/2025-01-13T09:20:44+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/donafenib-in-131i-refractory-differentiated-thyroid-cancer/2025-01-13T09:20:04+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/a-study-of-pralsetinib-versus-standard-of-care-soc-for-treatment-of-ret-mutated-medullary-thyroid-cancer-mtc.-acceleret-mtc2025-01-13T09:20:04+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/the-safety-and-effectiveness-of-rhtsh-in-radioiodine-treatment-for-patients-with-differentiated-thyroid-cancer.-dtc2025-01-13T09:20:03+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/laser-ablation-of-papillary-thyroid-microcarcinoma/2025-01-13T09:20:03+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/systematic-radioiodine-administration-3.7-gbq-i131-after-rhtsh-versus-decision-of-radioiodine-treatment-guided-by-a-post-operative-work-up-intermediate2025-01-13T09:20:03+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/multiple-target-kinase-inhibitor-and-anti-programmed-death-1-antibody-in-patients-with-advanced-thyroid-cancer/2025-01-31T10:45:14+00:00weekly0.7https://www.medthority.com/clinical-trials/thyroid-cancer/the-role-of-68-gallium-dotatate-petct-in-the-imaging-of-metastatic-thyroid-cancer/2025-01-13T09:20:02+00:00weekly0.7https://www.medthority.com/clinical-trials/lenvima/lenvatinib-and-iodine-therapy-in-treating-patients-with-radioactive-iodine-sensitive-differentiated-thyroid-cancer/2021-09-24T08:13:59+00:00weekly0.7https://www.medthority.com/clinical-trials/lenvima/lenvatinib-in-locally-advanced-invasive-thyroid-cancer/2021-09-24T08:13:59+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/a-trial-of-ak112-pd1vegf-bispecific-in-combination-with-chemotherapy-in-patients-with-nsclc/2025-01-13T09:18:53+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/sar408701-in-combination-with-pembrolizumab-and-pembrolizumab-alone-in-patients-with-non-squamous-non-small-cell-lung-cancer-nsq-nsclc-carmen-lc05/2025-01-13T09:18:53+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/study-of-pd-1-inhibitor-jtx-4014-alone-and-in-combination-with-vopratelimab-in-biomarker-selected-subjects-with-metastatic-nsclc-after-one-prior-platinum-containing-regimen-select/2025-01-13T09:18:53+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/jy025-is-a-first-line-treatment-for-egfr-mutated-nsclc-phase-ii-and-iii-clinical-trials-of-efficacy-and-safety/2025-01-13T09:18:53+00:00weekly0.7https://www.medthority.com/clinical-trials/imfinzi/study-of-durvalumab-following-radiation-therapy-in-patients-with-stage-3-unresectable-nsclc-ineligible-for-chemotherapy-duart/2025-05-05T14:22:41+00:00weekly0.7https://www.medthority.com/clinical-trials/imfinzi/a-study-of-neoadjuvantadjuvant-durvalumab-for-the-treatment-of-patients-with-resectable-non-small-cell-lung-cancer-aegean/2025-05-05T14:23:04+00:00weekly0.7https://www.medthority.com/clinical-trials/imfinzi/phase-iii-study-to-determine-efficacy-of-durvalumab-in-stage-ii-iii-non-small-cell-lung-cancer-nsclc-after-curative-intent-therapy.-mermaid-22025-05-05T14:23:23+00:00weekly0.7https://www.medthority.com/clinical-trials/imfinzi/a-study-of-durvalumab-as-consolidation-therapy-in-non-small-cell-lung-cancer-patients-pacific-5/2025-05-05T14:23:38+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/a-study-of-atezolizumab-and-tiragolumab-compared-with-durvalumab-in-participants-with-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer-nsclc-skyscraper-03/2025-01-13T09:18:55+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/a-study-of-relatlimab-plus-nivolumab-in-combination-with-chemotherapy-vs.-nivolumab-in-combination-with-chemotherapy-as-first-line-treatment-for-participants-with-stage-iv-or-recurrent-non-small-cell-lung-cancer-nsclc2025-01-13T09:18:55+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/clinical-trial-of-yh25448lazertinib-as-the-first-line-treatment-in-patients-with-egfr-mutation-positive-locally-advanced-or-metastatic-nsclc-laser301/2025-01-13T09:18:55+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/a-trial-of-shr-1316placebo-in-combination-with-chemotherapy-in-patients-with-resectable-nsclc/2025-01-13T09:18:54+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/trilaciclib-a-cdk-46-inhibitor-in-patients-receiving-docetaxel-for-metastatic-non-small-cell-lung-cancer-nsclc-preserve-4/2025-01-13T09:18:54+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/study-of-ds-1062a-in-advanced-or-metastatic-non-small-cell-lung-cancer-with-actionable-genomic-alterations-tropion-lung05/2025-01-13T09:18:54+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/study-of-ds-1062a-versus-docetaxel-in-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer-without-actionable-genomic-alterations-tropion-lung01/2025-01-13T09:18:54+00:00weekly0.7https://www.medthority.com/clinical-trials/nsclc/cab-axl-adc-safety-and-efficacy-study-in-adults-with-nsclc/2025-01-13T09:18:54+00:00weekly0.7https://www.medthority.com/clinical-trials/enhertu/trastuzumab-deruxtecan-in-participants-with-her2-mutated-metastatic-non-small-cell-lung-cancer-nsclc-destiny-lung02/2025-01-13T09:20:14+00:00weekly0.7https://www.medthority.com/clinical-trials/tagrisso/a-study-of-osimertinib-with-or-without-chemotherapy-versus-chemotherapy-alone-as-neoadjuvant-therapy-for-patients-with-egfrm-positive-resectable-non-small-cell-lung-cancer-neoadaura/2025-05-05T14:17:36+00:00weekly0.7https://www.medthority.com/clinical-trials/tagrisso/a-study-to-evaluate-chemotherapy-plus-osimertinib-against-chemotherapy-plus-placebo-in-patients-with-non-small-cell-lung-cancer-nsclc-compel/2025-05-05T14:22:20+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/the-pebbles-study-testing-a-strategy-for-preventing-eczema-and-food-allergy-in-high-risk-infants-pebbles/2025-01-13T09:18:18+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/adp101-for-oral-immunotherapy-in-food-allergic-children-and-adults/2025-01-13T09:18:18+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/ve416-for-treatment-of-food-allergy/2025-01-13T09:18:18+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/oral-immunotherapy-for-desensitization-in-children-adolescents-and-young-adults-with-hen-egg-allergy/2025-01-13T09:18:18+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/peanut-oral-immunotherapy-study-of-early-intervention-for-desensitization-poseidon/2025-01-13T09:18:17+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/oral-immunotherapy-for-peanut-allergic-patients/2025-01-13T09:18:17+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/the-treeat-study--can-early-introduction-of-tree-nuts-prevent-tree-nut-allergy-in-infants-with-peanut-allergy-treeat/2025-05-05T14:27:42+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/step-it-up---peanut-allergy-study-for-infants/2025-01-13T09:18:19+00:00weekly0.7https://www.medthority.com/clinical-trials/food-allergy/food-specific-and-component-ige-threshold-levels-that-predict-food-allergy-in-people-with-elevated-total-serum-ige-levels-and-atopic-dermatitis/2025-01-31T10:32:10+00:00weekly0.7https://www.medthority.com/clinical-trials/orencia/adjuvant-treatment-with-abatacept-to-promote-remission-during-peanut-oral-immunotherapy-atari/2021-09-24T08:14:08+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/dupilumab-and-milk-oit-for-the-treatment-of-cows-milk-allergy/2026-01-29T09:32:17+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/study-in-pediatric-subjects-with-peanut-allergy-to-evaluate-efficacy-and-safety-of-dupilumab-as-adjunct-to-ar101-peanut-oral-immunotherapy/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/study-to-evaluate-dupilumab-monotherapy-in-pediatric-patients-with-peanut-allergy/2021-09-24T08:13:33+00:00weekly0.7https://www.medthority.com/clinical-trials/abelacimab/safety-and-tolerability-of-abelacimab-maa868-vs.-rivaroxaban-in-patients-with-atrial-fibrillation-azalea-timi-712021-09-24T08:13:17+00:00weekly0.7https://www.medthority.com/clinical-trials/etripamil/revera-201-etripamil-in-atrial-fibrillation-phase-2/2021-09-24T08:13:39+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/a-study-to-evaluate-safety-and-tolerability-of-qls-101-in-ntg/2025-01-13T09:18:22+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/a-study-of-efficacy-and-safety-of-php-201-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension/2025-01-13T09:18:22+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/mrct-evaluating-ncx-470-vs.-latanoprost-in-subjects-with-open-angle-glaucoma-or-ocular-hypertension-denali2025-01-13T09:18:21+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/phase-3-trial-of-ncx-470-vs.-latanoprost-in-subjects-with-open-angle-glaucoma-or-ocular-hypertension-mont-blanc2025-01-13T09:18:21+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/dual-intravitreal-implantation-of-nt-501-encapsulated-cell-therapy-for-glaucoma/2025-01-13T09:18:21+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/nebivolol-0.5-1.0-or-timolol-0.5-suspension-compared-to-timolol-0.5-solution-to-treat-glaucomaocular-hypertension2025-01-13T09:18:21+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/bremen-eye-drops-versus-combigan-for-open-angle-glaucoma-or-intraocular-hypertension/2025-01-13T09:18:21+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/comparison-of-bimatoprost-sr-to-selective-laser-trabeculoplasty-in-patients-with-open-angle-glaucoma-or-ocular-hypertension/2025-01-13T09:18:20+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/clarifying-the-optimal-application-of-slt-therapy-trial-coast/2025-01-13T09:18:20+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/macular-pigment-and-visual-performance-in-glaucoma-patients/2025-01-13T09:18:20+00:00weekly0.7https://www.medthority.com/clinical-trials/glaucoma/evaluation-of-the-duration-of-effect-of-bimatoprost-sr-in-participants-with-open-angle-glaucoma-or-ocular-hypertension/2025-01-13T09:18:20+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/a-study-to-evaluate-the-safety-compared-to-iron-sucrose-efficacy-and-pharmacokinetics-of-ferumoxytol-for-the-treatment-of-iron-deficiency-anemia-ida-in-pediatric-subjects-with-chronic-kidney-disease-ckd/2025-01-13T09:17:54+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/study-to-evaluate-the-safety-and-efficacy-of-oral-vadadustat-in-pediatric-participants-with-anemia-of-chronic-kidney-disease-conversion/2025-01-13T09:17:54+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/study-to-evaluate-the-safety-and-efficacy-of-oral-vadadustat-in-pediatric-participants-with-anemia-of-chronic-kidney-disease-naive-to-erythropoiesis-stimulating-agents-correction/2025-01-13T09:17:53+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/pbf-1681-ferric-citrate-for-the-treatment-of-ida-in-patients-with-ndd-ckd/2025-01-13T09:17:53+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/investigating-the-efficacy-safety-and-pk-of-roxadustat-fg-4592-for-treatment-of-anemia-in-pediatric-patients-with-ckd/2025-01-13T09:17:53+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/a-study-to-learn-more-about-the-long-term-safety-and-effectiveness-of-molidustat-as-a-treatment-for-japanese-men-and-women-with-renal-anemia/2025-01-13T09:17:52+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/phase-iii-clinical-study-of-recombinant-erythropoiesis-stimulating-protein-injection-resp-in-the-treatment-of-anemia-in-hemodialysis-patients-with-chronic-renal-failure/2025-01-13T09:17:52+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/anemia-studies-in-ckd-erythropoiesis-via-a-novel-prolyl-hydroxylase-inhibitor-phi-daprodustat--iron-ascend-fe/2025-01-13T09:17:57+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/study-evaluating-the-efficacy-and-safety-of-dose-conversion-from-a-long-acting-erythropoiesis-stimulating-agent-mircera-to-three-times-weekly-oral-vadadustat-for-the-maintenance-treatment-of-anemia-in-hemodialysis-subjects/2025-01-13T09:17:57+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/study-of-the-efficacy-and-safety-of-pegol-sihematide-for-anemia-in-patients-with-chronic-kidney-disease-on-dialysis/2025-01-13T09:17:56+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/a-study-of-and017-to-treat-anemia-in-non-dialysis-dependent-chronic-kidney-disease-ndd-ckd-patients/2025-01-13T09:17:56+00:00weekly0.7https://www.medthority.com/clinical-trials/anaemia-associated-with-chronic-kidney-disease/a-study-of-efepoetin-alfa-in-treating-anaemia-associated-with-chronic-kidney-diseases-patient/2025-01-13T09:17:55+00:00weekly0.7https://www.medthority.com/clinical-trials/polycystic-kidney-disease/safety-of-lixivaptan-in-subjects-previously-treated-with-tolvaptan-for-autosomal-dominant-polycystic-kidney-disease-alert/2025-01-13T09:18:59+00:00weekly0.7https://www.medthority.com/clinical-trials/polycystic-kidney-disease/efficacy-and-safety-of-lixivaptan-in-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-action/2025-01-13T09:18:58+00:00weekly0.7https://www.medthority.com/clinical-trials/jinarc/a-study-to-see-if-tolvaptan-can-delay-dialysis-in-infants-and-children-who-at-enrollment-are-28-days-to-less-than-12-weeks-old-with-autosomal-recessive-polycystic-kidney-disease-arpkd/2025-01-13T09:20:36+00:00weekly0.7https://www.medthority.com/clinical-trials/jinarc/a-study-to-see-if-tolvaptan-is-safe-in-infants-and-children-who-at-enrollment-are-28-days-to-less-than-18-years-old-with-autosomal-recessive-polycystic-kidney-disease-arpkd/2025-01-13T09:20:36+00:00weekly0.7https://www.medthority.com/clinical-trials/polycystic-kidney-disease/a-study-to-evaluate-the-effects-of-glpg2737-in-participants-with-autosomal-dominant-polycystic-kidney-disease-adpkd/2025-01-13T09:18:58+00:00weekly0.7https://www.medthority.com/clinical-trials/polycystic-kidney-disease/roll-over-study-to-assess-safety-of-lixivaptan-in-participants-with-adpkd-who-completed-study-pa-adpkd-303/2025-01-13T09:18:58+00:00weekly0.7https://www.medthority.com/clinical-trials/polycystic-kidney-disease/study-of-the-efficacy-and-safety-of-tesevatinib-in-subjects-with-adpkd/2025-01-13T09:18:58+00:00weekly0.7https://www.medthority.com/clinical-trials/polycystic-kidney-disease/a-trial-of-bardoxolone-methyl-in-patients-with-adpkd---falcon-falcon/2025-01-13T09:18:57+00:00weekly0.7https://www.medthority.com/clinical-trials/lokelma/a-study-to-evaluate-the-effect-of-sodium-zirconium-cyclosilicate-on-chronic-kidney-disease-ckd-progression-in-participants-with-ckd-and-hyperkalaemia-or-at-risk-of-hyperkalaemia-stabilize-ckd/2025-05-05T14:25:20+00:00weekly0.7https://www.medthority.com/clinical-trials/lokelma/study-of-the-effect-of-szc-on-serum-potassium-and-serum-bicarbonate-in-patients-with-hyperkalemia-and-metabolic-acidosis-associated-with-chronic-kidney-disease-neutralize/2025-05-05T14:25:47+00:00weekly0.7https://www.medthority.com/clinical-trials/lokelma/a-study-in-children-with-hyperkalaemia-between-birth-and-18-years-of-age-to-evaluate-doses-of-sodium-zirconium-cyclosilicate-szc-for-correction-of-hyperkalaemia-and-effectiveness-of-same-dose-to-maintain-normokalaemia/2025-05-05T14:13:08+00:00weekly0.7https://www.medthority.com/clinical-trials/veltassa/cardiovascular-and-renal-treatment-in-heart-failure-patients-with-hyperkalaemia-or-at-high-risk-of-hyperkalaemia-care-hk-in-hf/2025-01-13T09:20:48+00:00weekly0.7https://www.medthority.com/clinical-trials/veltassa/pharmacodynamic--safety-of-patiromer-in-children--adolescents-2-18-yrs-with-chronic-kidney-disease-and-hyperkalemia-emerald/2025-01-13T09:20:48+00:00weekly0.7https://www.medthority.com/clinical-trials/veltassa/patiromer-utility-as-an-adjunct-treatment-in-patients-needing-urgent-hyperkalemia-management-platinum/2025-01-13T09:20:48+00:00weekly0.7https://www.medthority.com/clinical-trials/fluid-and-electrolyte-disorders/a-comparative-study-of-zg-801-and-placebo-in-patients-with-hyperkalemia/2025-01-13T09:18:16+00:00weekly0.7https://www.medthority.com/clinical-trials/fluid-and-electrolyte-disorders/a-study-evaluating-the-safety-and-efficacy-of-rdx013-for-the-treatment-of-hyperkalemia-redukx/2025-01-13T09:18:16+00:00weekly0.7https://www.medthority.com/clinical-trials/ultomiris/study-of-ravulizumab-in-proliferative-lupus-nephritis-ln-or-immunoglobulin-a-nephropathy-igan/2025-01-13T09:20:48+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/phase-3-study-of-anifrolumab-in-adult-patients-with-active-proliferative-lupus-nephritis-iris/2025-05-05T14:10:19+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/study-of-safety-efficacy-and-tolerability-of-secukinumab-versus-placebo-in-combination-with-soc-therapy-in-patients-with-active-lupus-nephritis-selune/2025-01-13T09:20:12+00:00weekly0.7https://www.medthority.com/clinical-trials/tremfya/a-study-of-guselkumab-in-participants-with-active-lupus-nephritis-orchid-ln/2025-01-13T09:20:47+00:00weekly0.7https://www.medthority.com/clinical-trials/gazyvaro/a-study-evaluating-the-efficacy-and-safety-of-obinutuzumab-in-participants-with-primary-membranous-nephropathy/2025-01-13T09:20:35+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/atrasentan-in-patients-with-iga-nephropathy-align/2025-01-13T09:18:23+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/study-of-efficacy-and-safety-of-lnp023-in-primary-iga-nephropathy-patients-applause-igan/2025-01-13T09:18:25+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/study-of-alxn2050-in-proliferative-lupus-nephritis-ln-and-immunoglobulin-a-nephropathy-igan/2025-01-13T09:18:25+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/safety-and-efficacy-study-of-vis649-for-iga-nephropathy/2025-01-13T09:18:24+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/a-rollover-extension-program-rep-to-evaluate-the-long-term-safety-and-tolerability-of-open-label-iptacopanlnp023-in-participants-with-primary-iga-nephropathy/2025-01-13T09:18:24+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/atacicept-in-subjects-with-iga-nephropathy-origin/2025-01-13T09:18:24+00:00weekly0.7https://www.medthority.com/clinical-trials/glomerulonephritis/safety-efficacy-and-tolerability-of-ianalumab-versus-placebo-combination-with-soc-therapy-in-participants-with-active-lupus-nephritis-sirius-ln/2025-01-13T09:18:24+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-coronary-syndrome/effect-of-dlbs1033-after-primary-pci-in-patients-with-ste-acs/2025-01-13T09:17:33+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-coronary-syndrome/mt1002-phase-ii-study-in-acs-patients-with-pci/2025-01-13T09:17:33+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-coronary-syndrome/study-to-investigate-csl112-in-subjects-with-acute-coronary-syndrome-aegis-ii/2025-01-13T09:17:32+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-coronary-syndrome/passivation-of-vulnerable-plaque-with-azd5718-in-acute-coronary-syndrome-passivate/2025-01-13T09:17:32+00:00weekly0.7https://www.medthority.com/clinical-trials/brilique/percutaneous-coronary-intervention-followed-by-monotherapy-instead-of-dual-antiplatelet-therapy-in-the-setting-of-acute-coronary-syndromes-the-neo-mindset-trial-neomindset/2025-01-13T09:20:11+00:00weekly0.7https://www.medthority.com/clinical-trials/acute-coronary-syndrome/low-dose-interleukin-2-for-the-reduction-of-vascular-inflammation-in-acute-coronary-syndromes---ivory-ivory/2025-01-13T09:17:32+00:00weekly0.7https://www.medthority.com/clinical-trials/repatha/evolocumab-in-acute-coronary-syndrome-evacs/2025-01-13T09:20:44+00:00weekly0.7https://www.medthority.com/clinical-trials/repatha/evolocumab-in-patients-with-acute-mi-evacs-ii/2025-01-13T09:20:43+00:00weekly0.7https://www.medthority.com/clinical-trials/brilique/platelet-inhibition-with-ticagrelor-60-mg-versus-ticagrelor-90-mg-in-elderly-patients-with-acs-plinytheelder/2025-01-13T09:20:12+00:00weekly0.7https://www.medthority.com/clinical-trials/brilique/evaluation-of-safety-and-efficacy-of-two-ticagrelor-based-de-escalation-antiplatelet-strategies-in-acute-coronary-syndrome-electra-sirio/2025-01-13T09:20:11+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/efficacy-and-safety-apt-1011-in-adult-subjects-with-eosinophilic-esophagitis-eoe-flute-2/2025-01-13T09:18:13+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/a-study-to-assess-the-efficacy-safety-and-tolerability-of-irl201104-in-adults-with-active-eosinophilic-esophagitis/2025-01-13T09:18:13+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/study-to-determine-the-efficacy-and-safety-of-dupilumab-in-adult-and-adolescent-patients-with-eosinophilic-esophagitis-eoe/2025-01-13T09:20:14+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/study-to-investigate-the-efficacy-and-safety-of-dupilumab-in-pediatric-patients-with-active-eosinophilic-esophagitis-eoe-eoe-kids/2025-01-13T09:20:14+00:00weekly0.7https://www.medthority.com/clinical-trials/jorveza/maintenance-of-remission-with-budesonide-orodispersible-tablets-vs.-placebo-in-eosinophilic-esophagitis-eos-22025-01-13T09:20:36+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/a-study-of-benralizumab-in-patients-with-eosinophilic-esophagitis-messina/2025-05-05T14:25:06+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-of-an-ad26.rsv.pref-based-regimen-in-the-prevention-of-reverse-transcriptase-polymerase-chain-reaction-rt-pcr-confirmed-respiratory-syncytial-virus-rsv-mediated-lower-respiratory-tract-disease-in-adults-aged-65-years-and-older-cypress2025-01-13T09:19:07+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/efficacy-and-safety-of-mk-1654-in-infants-mk-1654-004/2025-01-13T09:19:06+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/mk-1654-in-infants-and-children-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-mk-1654-007/2025-01-13T09:19:06+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-to-evaluate-the-safety-and-efficacy-of-mrna-1345-vaccine-targeting-respiratory-syncytial-virus-rsv-in-adults-60-years-of-age/2025-01-13T09:19:06+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/study-of-a-live-attenuated-respiratory-syncytial-virus-vaccine-in-infants-and-toddlers-vad00001/2025-01-13T09:19:06+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/study-to-evaluate-the-efficacy-immunogenicity-and-safety-of-rsvpref-in-adults.-renoir2025-01-13T09:19:05+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-trial-to-evaluate-the-efficacy-and-safety-of-rsvpref-in-infants-born-to-women-vaccinated-during-pregnancy/2025-01-13T09:19:05+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-to-evaluate-the-safety-of-medi8897-for-the-prevention-of-medically-attended-respiratory-syncytial-virusrsv-lower-respiratory-track-infection-lrti-in-high-risk-children/2025-05-05T14:12:05+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-to-assess-edp-938-for-the-treatment-of-acute-upper-respiratory-tract-infection-with-respiratory-syncytial-virus-in-adult-subjects-rsvp/2025-01-13T09:19:05+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/efficacy-study-of-gsks-investigational-respiratory-syncytial-virus-rsv-vaccine-in-adults-aged-60-years-and-above/2025-01-13T09:19:57+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-of-3-lots-of-an-investigational-vaccine-against-respiratory-syncytial-virus-rsv-in-adults-aged-60-years-and-above/2025-01-13T09:19:38+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-phase-iii-double-blind-study-to-assess-safety-and-efficacy-of-an-rsv-maternal-unadjuvanted-vaccine-in-pregnant-women-and-infants-born-to-vaccinated-mothers-grace/2021-11-26T15:04:00+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/immunogenicity-safety-reactogenicity-and-persistence-of-an-investigational-respiratory-syncytial-virus-rsv-vaccine-in-adults-aged-60-years-and-above/2025-01-13T09:19:08+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-of-rilematovir-jnj-53718678-in-adult-outpatients-with-respiratory-syncytial-virus-rsv-infection-primrose/2025-01-13T09:19:08+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-of-rilematovir-in-infants-and-children-and-subsequently-in-neonates-hospitalized-with-acute-respiratory-tract-infection-due-to-respiratory-syncytial-virus-rsv-daisy/2025-01-13T09:19:07+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-of-an-adenovirus-serotype-26-pre-fusion-conformation-stabilized-f-protein-ad26.-rsv.-pref-based-respiratory-syncytial-virus-rsv-vaccine-in-the-prevention-of-lower-respiratory-tract-disease-in-adults-aged-60-years-and-older-evergreen2025-01-13T09:19:07+00:00weekly0.7https://www.medthority.com/clinical-trials/respiratory-syncytial-virus-rsv/a-study-of-an-ad26.rsv.-pref-based-vaccine-in-adults-aged-18-to-59-years-including-adults-at-high-risk-for-severe-rsv-infection2025-01-13T09:19:07+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/a-study-of-lirentelimab-ak002-in-patients-with-active-eosinophilic-esophagitis-kryptos/2025-01-13T09:18:14+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/a-study-to-assess-the-safety-and-efficacy-of-oral-etrasimod-in-adult-participants-with-eosinophilic-esophagitis-voyage/2025-01-13T09:18:14+00:00weekly0.7https://www.medthority.com/clinical-trials/eosinophilic-esophagitis/safety-study-of-cc-93538-in-adult-and-adolescent-participants-with-eosinophilic-esophagitis/2025-01-13T09:18:14+00:00weekly0.7https://www.medthority.com/clinical-trials/entyvio/the-impact-of-anti-tnf-exposure-on-vedolizumab-effectiveness/2021-09-24T08:13:38+00:00weekly0.7https://www.medthority.com/clinical-trials/avonex/study-of-evobrutinib-in-participants-with-relapsing-multiple-sclerosis--evolution-rms2-/2021-09-24T08:13:21+00:00weekly0.7https://www.medthority.com/clinical-trials/jinarc/tolvaptan-phase-3-efficacy-and-safety-study-in-adpkd--tempo3-4-/2022-02-21T15:04:10+00:00weekly0.7https://www.medthority.com/clinical-trials/epidyolex/a-study-to-investigate-the-efficacy-and-safety-of-cannabidiol--gwp42003-p--cbd--as-adjunctive-treatm/2021-09-24T08:13:38+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/long-term-benefits-and-safety-of-systemic-psoriasis-therapy--german-registry-on-the-treatment-of-pso/2021-09-24T08:13:29+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/a-study-of-carboplatin-paclitaxel-nab-paclitaxel-chemotherapy-with-or-without-pembrolizumab--mk-3475/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/alecensa/a-study-comparing-alectinib-with-crizotinib-in-treatment-naive-anaplastic-lymphoma-kinase-positive-a/2024-10-17T08:55:50+00:00weekly0.7https://www.medthority.com/clinical-trials/jinarc/tolvaptan-open-label-pilot-efficacy--tolerability-and-safety-study-in-adpkd--tempo-2-4-/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/ondexxya/a-study-in-patients-with-acute-major-bleeding-to-evaluate-the-ability-of-andexanet-alfa-to-reverse-t/2021-12-16T15:17:48+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/pembrolizumab-plus-bevacizumab-for-treatment-of-brain-metastases-in-metastatic-melanoma-or-non-small/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/ocrevus/a-study-of-ocrelizumab-in-children-and-adolescents-with-relapsing-remitting-multiple-sclerosis/2023-09-07T13:21:38+00:00weekly0.7https://www.medthority.com/clinical-trials/juluca/regimen-switch-to-dolutegravir---rilpivirine-from-current-antiretroviral-regimen-in-human-immunodefi/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/comparison-of-secukinumab-versus-guselkumab-in-clearing-psoriatic-plaques-refractory-to-ustekinumab-/2024-03-05T14:55:41+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-study-of-benralizumab-to-reduce-ocs-use-in-patients-with-uncontrolled-asthma-on-/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/genvoya/pharmacokinetics--safety--and-antiviral-activity-of-the-elvitegravir-cobicistat-emtricitabine-tenofo/2021-09-24T08:13:43+00:00weekly0.7https://www.medthority.com/clinical-trials/spinraza/a-study-of-multiple-doses-of-nusinersen--isis-396443--delivered-to-infants-with-genetically-diagnose/2024-10-18T10:31:16+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--versus-placebo-in-combination-with-neoadjuvant-chemotherapy---adjuv/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/a-study-of-the-bruton-s-tyrosine-kinase-inhibitor--pci-32765--ibrutinib---in-combination-with-rituxi/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pemetrexed-platinum-chemotherapy-with-or-without-pembrolizumab--mk-3475--in-participants-wi/2024-01-30T15:08:55+00:00weekly0.7https://www.medthority.com/clinical-trials/hemlibra/a-study-to-evaluate-the-efficacy--safety--pharmacokinetics--and-pharmacodynamics-of-emicizumab-given/2021-09-24T08:13:48+00:00weekly0.7https://www.medthority.com/clinical-trials/genvoya/open-label-study-to-evaluate-switching-from-a-tdf-containing-combination-regimen-to-a-taf-containing/2021-09-24T08:13:43+00:00weekly0.7https://www.medthority.com/clinical-trials/opdivo/a-study-to-compare-bms-936558-to-the-physician-s-choice-of-either-dacarbazine-or-carboplatin-and-pac/2024-01-30T16:04:35+00:00weekly0.7https://www.medthority.com/clinical-trials/humira/post-marketing-surveillance-of-adalimumab-in-korean-hidradenitis-suppurativa-subjects--hs-rpms-/2024-03-12T15:19:48+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/safety-and-efficacy-study-of-enzalutamide-in-patients-with-nonmetastatic-castration-resistant-prosta-1/2024-12-17T10:40:16+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/a-study-of-arn-509-in-men-with-non-metastatic-castration-resistant-prostate-cancer--spartan-/2024-10-07T08:23:35+00:00weekly0.7https://www.medthority.com/clinical-trials/gazyvaro/a-study-comparing-ro5072759--ga101--1000-mg-versus-2000-mg-in-patients-with-previously-untreated-chr/2021-09-24T08:13:42+00:00weekly0.7https://www.medthority.com/clinical-trials/juluca/nct02429791-regimen-switch-to-dolutegravir---rilpivirine-from-current-antiretroviral-regimen-in-huma/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/hemlibra/a-clinical-trial-to-evaluate-prophylactic-emicizumab-versus-no-prophylaxis-in-hemophilia-a-participa/2021-09-24T08:13:48+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/a-randomized-double-blind-phase-iii-study-of-ibrutinib-during-and-following-autologous-stem-cell-tra/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/empliciti/phase-iii-study-of-lenalidomide-and-dexamethasone-with-or-without-elotuzumab-to-treat-relapsed-or-re/2026-02-02T09:55:20+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/evaluation-of-dupilumab-in-children-with-uncontrolled-asthma--voyage-/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/a-study-of-abiraterone-acetate-plus-prednisone-with-or-without-abemaciclib--ly2835219--in-participan/2025-05-05T14:29:54+00:00weekly0.7https://www.medthority.com/clinical-trials/opdivo/study-of-nivolumab--bms-936558--vs--everolimus-in-pre-treated-advanced-or-metastatic-clear-cell-rena/2024-02-01T11:06:16+00:00weekly0.7https://www.medthority.com/clinical-trials/spinraza/a-study-for-participants-with-spinal-muscular-atrophy--sma--who-previously-participated-in-nusinerse/2024-10-18T10:30:09+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--compared-to-platinum-based-chemotherapies-in-participants-with-meta/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/emgality/a-study-of-ly2951742--galcanezumab--in-participants-with-cluster-headache/2023-05-16T14:30:30+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/study-to-evaluate-efficacy-and-safety-of-benralizumab-in-reducing-oral-corticosteroid-use-in-adult-p/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/pembro-and-vorinostat-for-patients-with-stage-iv-non-small-cell-lung-cancer-nsclc/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/emgality/evaluation-of-galcanezumab-in-the-prevention-of-episodic-migraine--the-evolve-1-study--evolve-1-/2023-05-16T14:37:36+00:00weekly0.7https://www.medthority.com/clinical-trials/kevzara/efficacy-and-safety-of-sarilumab-and-adalimumab-monotherapy-in-patients-with-rheumatoid-arthritis--s/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/study-on-olaparib-plus-abiraterone-as-first-line-therapy-in-men-with-metastatic-castration-resistant/2025-05-05T14:13:28+00:00weekly0.7https://www.medthority.com/clinical-trials/vyepti/a-multicenter-assessment-of-ald403-in-frequent-episodic-migraine-promise-1/2023-05-16T07:38:12+00:00weekly0.7https://www.medthority.com/clinical-trials/veltassa/a-two-part-single-blind-phase-3-study-evaluating-the-efficacy-and-safety-of-patiromer-for-the-treatment/2022-02-03T15:37:57+00:00weekly0.7https://www.medthority.com/clinical-trials/emgality/a-study-of-galcanezumab--ly2951742--in-adults-with-treatment-resistant-migraine--conquer-/2023-05-16T14:33:23+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/a-phase-3-study-of-ibrutinib--pci-32765--versus-ofatumumab-in-patients-with-relapsed-or-refractory-c/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/humira/effectiveness-of-adalimumab-in-moderate-to-severe-hidradenitis-suppurativa-patients---a-multi-countr/2024-03-12T15:19:48+00:00weekly0.7https://www.medthority.com/clinical-trials/ocrevus/a-study-of-ocrelizumab-in-comparison-with-interferon-beta-1a--rebif--in-participants-with-relapsing-/2023-09-07T13:29:31+00:00weekly0.7https://www.medthority.com/clinical-trials/gemzar/ascent-study-of-sacituzumab-govitecan-in-refractory-relapsed-triple-negative-breast-cancer--ascent-/2021-09-24T08:13:43+00:00weekly0.7https://www.medthority.com/clinical-trials/kisqali/study-of-efficacy-and-safety-of-lee011-in-men-and-postmenopausal-women-with-advanced-breast-cancer--/2024-02-01T11:37:38+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/efficacy-and-safety-study-of-dupilumab-in-patients-with-persistent-asthma/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-of-benralizumab-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/long-term-safety-evaluation-of-dupilumab-in-patients-with-asthma--liberty-asthma-traverse-/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/lorviqua/a-study-of-pf-06463922-an-alk-ros1-inhibitor-in-patients-with-advanced-non-small-cell-lung-cancer-wi/2024-01-30T15:46:51+00:00weekly0.7https://www.medthority.com/clinical-trials/kalydeco/a-study-evaluating-the-efficacy-and-safety-of-vx-445-tezacaftor-ivacaftor-in-cystic-fibrosis-subject/2021-09-24T08:13:56+00:00weekly0.7https://www.medthority.com/clinical-trials/sprycel/a-phase-ii-study-of-dasatinib-in-children-and-adolescents-with-newly-diagnosed-chronic-phase-cml-or-/2021-09-24T08:14:22+00:00weekly0.7https://www.medthority.com/clinical-trials/cometriq/a-study-of-cabozantinib--xl184--vs-everolimus-in-subjects-with-metastatic-renal-cell-carcinoma--mete/2024-03-05T10:29:43+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-study-of-benralizumab-in-patients-with-uncontrolled-asthma-on-medium-to-high-dos/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-two-doses-of-mk-3475--pembrolizumab--versus-docetaxel-in-previously-treated-participants-wi/2024-02-01T13:49:33+00:00weekly0.7https://www.medthority.com/clinical-trials/cabometyx/study-of-cabozantinib--xl184--vs-placebo-in-subjects-with-hepatocellular-carcinoma-who-have-received/2024-02-01T13:58:10+00:00weekly0.7https://www.medthority.com/clinical-trials/gemzar/study-of-immu-132-in-hr--her2--mbc--tropics-02-/2021-09-24T08:13:43+00:00weekly0.7https://www.medthority.com/clinical-trials/imfinzi/a-global-study-to-assess-the-effects-of-medi4736-following-concurrent-chemoradiation-in-patients-wit/2021-09-24T08:13:52+00:00weekly0.7https://www.medthority.com/clinical-trials/cimzia/a-study-to-evaluate-the-efficacy--safety--and-drug-concentration-of-certolizumab-pegol--czp--in-chil/2024-03-05T14:09:19+00:00weekly0.7https://www.medthority.com/clinical-trials/januvia/a-research-study-comparing-a-new-medicine-oral-semaglutide-to-sitagliptin-in-people-with-type-2-diab/2021-09-24T08:13:54+00:00weekly0.7https://www.medthority.com/clinical-trials/vyepti/evaluate-efficacy-safety-of-eptinezumab-administered-intravenously-in-subjects-experiencing-acute/2023-05-16T07:33:07+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/a-three-part-randomized--double-blind--placebo-controlled-study-to-investigate-the-efficacy-and-safe/2024-03-05T13:54:52+00:00weekly0.7https://www.medthority.com/clinical-trials/entresto/efficacy-and-safety-of-lcz696-compared-to-valsartan--on-morbidity-and-mortality-in-heart-failure-pat/2021-09-24T08:13:37+00:00weekly0.7https://www.medthority.com/clinical-trials/avastin/a-study-of-atezolizumab-in-combination-with-carboplatin-plus-----paclitaxel-with-or-without-bevacizu/2024-02-27T15:10:28+00:00weekly0.7https://www.medthority.com/clinical-trials/biktarvy/safety-and-efficacy-of-bictegravir-emtricitabine-tenofovir-alafenamide-versus-dolutegravir---emtrici/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/delstrigo/safety-and-efficacy-of-a-switch-to-mk-1439a-in-human-immunodeficiency-virus--hiv-1--infected-partici/2021-09-24T08:13:32+00:00weekly0.7https://www.medthority.com/clinical-trials/ondexxya/trial-of-andexanet-in-ich-patients-receiving-an-oral-fxa-inhibitor/2021-12-16T15:10:43+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/a-study-of-ibrutinib-in-combination-with-bendamustine-and-rituximab-in-patients-with-relapsed-or-ref/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/biktarvy/safety-and-efficacy-of-switching-from-regimens-consisting-of-boosted-atazanavir-or-darunavir-plus-ei/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/ilumetri/a-study-to-evaluate-the-efficacy-and-safety-of-subcutaneous-mk-3222--followed-by-an-optional-long-te/2021-09-24T08:13:50+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-study-of-benralizumab-added-to-high-dose-inhaled-corticosteroid-plus-laba-in-pat/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/blincyto/phase-3-trial-of-blinatumomab-vs-standard-chemotherapy-in-pediatric-subjects-with-hr-first-relapse-b/2024-02-27T15:55:51+00:00weekly0.7https://www.medthority.com/clinical-trials/brintellix/active-reference--fluoxetine--fixed-dose-study-of-vortioxetine-in-paediatric-patients-aged-12-to-17-/2021-09-24T08:13:24+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--or-placebo-given-with-best-supportive-care-in-asian-participants-wi/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/emgality/evaluation-of-galcanezumab-in-the-prevention-of-chronic-migraine--regain-/2023-05-16T14:26:36+00:00weekly0.7https://www.medthority.com/clinical-trials/emgality/evaluation-of-efficay---safety-of-galcanezumab-in-the-prevention-of-episodic-migraine--the-evolve-2-/2023-05-16T14:23:26+00:00weekly0.7https://www.medthority.com/clinical-trials/skyrizi/a-study-of-the-safety-and-efficacy-of-risankizumab-in-adult-participants-with-plaque-psoriasis-who-h/2021-09-24T08:14:20+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab-with-or-without-platinum-based-combination-chemotherapy-versus-chemotherapy-a/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/a-study-to-compare-safety-and-efficacy-of-upadacitinib-to-dupilumab-in-adult-participants-with-moder/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/ibrance/palbociclib--pd-0332991--combined-with-fulvestrant-in-hormone-receptor--her2-negative-metastatic-bre/2021-09-24T08:13:50+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/a-randomized--multicenter--open-label--phase-3-study-of-acalabrutinib--acp-196--in-combination-with-/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/autologous-transplantation-after-a-rituximab-ibrutinib-ara-c-containing-induction-in-generalized-man/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--in-participants-with-metastatic-castration-resistant-prostate-cance/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/a-52-week--plus-extension-until-commercialization---single-arm-study-to-evaluate-psoriasis-severity-/2024-02-13T15:50:13+00:00weekly0.7https://www.medthority.com/clinical-trials/jinarc/dose-finding-study-of-new-tolvaptan-formulation-in-subjects-with-adpkd/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/zykadia/ldk378-versus-chemotherapy-in-previously-untreated-patients-with-alk-rearranged-non-small-cell-lung-/2024-10-22T14:05:34+00:00weekly0.7https://www.medthority.com/clinical-trials/darzalex/addition-of-daratumumab-to-combination-of-bortezomib-and-dexamethasone-in-participants-with-relapsed/2024-03-05T12:53:48+00:00weekly0.7https://www.medthority.com/clinical-trials/kyprolis/phase-3-study-with-carfilzomib-and-dexamethasone-versus-velcade-and-dexamethasone-for-relapsed-multi/2024-02-02T09:19:29+00:00weekly0.7https://www.medthority.com/clinical-trials/herceptin/efficacy-and-safety-study-of-eg12014-compared-with-herceptin-in-subjects-with-her2-positive-early-br/2021-09-24T08:13:49+00:00weekly0.7https://www.medthority.com/clinical-trials/jinarc/8-week-study-of-tolvaptan-dose-forms-in-autosomal-dominant-polycystic-kidney-disease--adpkd---noctur/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/kalydeco/a-phase-3-study-of-vx-445-combination-therapy-in-cystic-fibrosis--cf--subjects-heterozygous-for-f508/2021-09-24T08:13:56+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--vs--best-supportive-care-in-participants-with-previously-systemical/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/avastin/a-study-of-atezolizumab-in-combination-with-bevacizumab-versus-sunitinib-in-participants-with-untrea/2021-09-24T08:13:21+00:00weekly0.7https://www.medthority.com/clinical-trials/herceptin/a-study-of-pertuzumab-in-addition-to-chemotherapy-and-trastuzumab-as-adjuvant-therapy-in-participant/2024-10-22T15:03:12+00:00weekly0.7https://www.medthority.com/clinical-trials/hemlibra/efficacy--safety--and-pharmacokinetic-study-of-prophylactic-emicizumab-versus-no-prophylaxis-in-hemo/2021-09-24T08:13:48+00:00weekly0.7https://www.medthority.com/clinical-trials/ocrevus/a-study-to-evaluate-ocrelizumab-treatment-in-participants-with-progressive-multiple-sclerosis--conso/2023-09-07T13:02:33+00:00weekly0.7https://www.medthority.com/clinical-trials/biktarvy/safety-and-efficacy-of-switching-from-dolutegravir-and-abc-3tc-or-abc-dtg-3tc-to-b-f-taf-in-hiv-1-in/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/imnovid/safety-and-efficacy-of-pomalidomide--bortezomib-and-low-dose-dexamethasone-in-subjects-with-relapsed/2021-09-24T08:13:53+00:00weekly0.7https://www.medthority.com/clinical-trials/imatinib-mesylate/an-efficacy-study-comparing-ponatinib-versus-imatinib--administered-in-combination-with-reduced-inte/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/kalydeco/a-phase-2-study-to-evaluate-efficacy-and-safety-of-vx-561-in-subjects-aged-18-years-and-older-with-c/2021-09-24T08:13:56+00:00weekly0.7https://www.medthority.com/clinical-trials/kalydeco/a-study-evaluating-the-long-term-safety-of-vx-445-combination-therapy/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/bavencio/avelumab-in-subjects-with-merkel-cell-carcinoma--javelin-merkel-200-/2024-03-12T11:56:18+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/assessment-of-the-safety-and-efficacy-of-dupilumab-in-children-with-asthma--liberty-asthma-excursion/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/solid-organ-transplantation/efficacy-and-safety-of-everolimus-in-liver-transplant-recipients-of-living-donor-liver-transplants/2021-09-24T08:14:21+00:00weekly0.7https://www.medthority.com/clinical-trials/lenvima/a-multicenter--randomized--double-blind--placebo-controlled--phase-3-trial-of-lenvatinib--e7080--in-/2024-02-02T10:55:09+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/study-of-safety--tolerability--and-efficacy-of-secukinumab-in-subjects-with-moderate-to-severe-palmo/2021-09-24T08:13:27+00:00weekly0.7https://www.medthority.com/clinical-trials/hemlibra/a-study-of-emicizumab-administered-subcutaneously--sc--in-pediatric-participants-with-hemophilia-a-a/2021-09-24T08:13:48+00:00weekly0.7https://www.medthority.com/clinical-trials/tafinlar/study-of-selective-braf-kinase-inhibitor-dabrafenib-monotherapy-twice-daily-and-in-combination-with-/2024-02-27T13:50:05+00:00weekly0.7https://www.medthority.com/clinical-trials/dexmedetomidine/the-neuroprotective-effects-of-dexmedetomidine-during-brain-surgery/2024-10-15T07:33:17+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/a-study-of-abiraterone-acetate-plus-low-dose-prednisone-plus-androgen-deprivation-therapy--adt--vers/2024-12-17T10:39:30+00:00weekly0.7https://www.medthority.com/clinical-trials/brilique/prevention-of-cardiovascular-events--eg--death-from-heart-or-vascular-disease--heart-attack--or-stro/2022-02-08T07:44:34+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--in-participants-with-relapsed-or-refractory-primary-mediastinal-lar/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/entresto/single-dose-study-to-evaluate-safety--tolerability-and-pharmacokinetics-of-lcz696-followed-by-a-52-w/2021-09-24T08:13:37+00:00weekly0.7https://www.medthority.com/clinical-trials/bosulif/impact-of-bosutinib-on-safety--tolerability--biomarkers-and-clinical-outcomes-in-dementia-with-lewy-/2024-03-05T14:45:03+00:00weekly0.7https://www.medthority.com/clinical-trials/cimzia/multicenter-study-evaluating-certolizumab-pegol-compared-to-placebo-in-subjects-with-axspa-without-x/2024-03-05T14:20:27+00:00weekly0.7https://www.medthority.com/clinical-trials/vimpat/efficacy-and-safety-of-lacosamide-as-adjunctive-therapy-in-subjects--1-month-to--4-years-with-partia/2024-10-21T09:57:39+00:00weekly0.7https://www.medthority.com/clinical-trials/lynparza/olaparib-treatment-in-relapsed-breast-cancer-susceptibility-gene--brca--mutated-ovarian-cancer-patie/2025-05-05T14:14:48+00:00weekly0.7https://www.medthority.com/clinical-trials/cholib/simvastatin-in-secondary-progressive-multiple-sclerosis-ms-opt-/2024-02-27T11:20:40+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/an-open-label--prospective--non-randomized--multicenter-study-to-evaluate-clear-skin-effect-on-healt/2021-09-24T08:13:27+00:00weekly0.7https://www.medthority.com/clinical-trials/simdax/repetitive-levosimendan-infusion-for-patients-with-advanced-chronic-heart-failure--leodor-/2021-09-24T08:14:19+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/a-phase-3b--multicenter--open-label--pci-32765--ibrutinib--long-term-extension-study/2021-09-24T08:13:51+00:00weekly0.7https://www.medthority.com/clinical-trials/kalydeco/a-study-to-evaluate-the-safety-of-long-term-ivacaftor-treatment-in-subjects-with-cystic-fibrosis-who/2021-09-24T08:13:55+00:00weekly0.7https://www.medthority.com/clinical-trials/benlysta/a-study-of-belimumab-administered-subcutaneously-in-subjects-with-systemic-lupus-erythematosus--sle-/2024-10-22T13:03:05+00:00weekly0.7https://www.medthority.com/clinical-trials/cyramza/a-study-of-ramucirumab--ly3009806--in-combination-with-capecitabine-and-cisplatin-in-participants-wi/2024-03-05T13:08:19+00:00weekly0.7https://www.medthority.com/clinical-trials/keppra/a-study-to-investigate-the-safety-of-the-drugs-topiramate-and-levetiracetam-in-treating-children-rec/2021-09-24T08:13:57+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/pivotal-study-to-assess-the-efficacy--safety-and-tolerability-of-dupilumab-in-patients-with-moderate/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/ocrevus/a-study-to-evaluate-the-efficacy-and-safety-of-ocrelizumab-in-adults-with-primary-progressive-multip/2023-09-07T13:15:11+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/a-study-of-pembrolizumab--mk-3475--for-first-line-treatment-of-recurrent-or-metastatic-squamous-cell/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/prostate-cancer/a-study-for-subjects-with-prostate-cancer-who-previously-participated-in-an-enzalutamide-clinical-st/2024-12-17T10:26:58+00:00weekly0.7https://www.medthority.com/clinical-trials/sprycel/therapy-of-early-chronic-phase-chronic-myelogenous-leukemia--cml--with-dasatinib/2021-09-24T08:14:22+00:00weekly0.7https://www.medthority.com/clinical-trials/biktarvy/safety-and-efficacy-of-bictegravir-emtricitabine-tenofovir-alafenamide-versus-dolutegravir---emtrici-1/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/darzalex/a-study-comparing-daratumumab--lenalidomide--and-dexamethasone-with-lenalidomide-and-dexamethasone-i/2024-03-05T12:44:19+00:00weekly0.7https://www.medthority.com/clinical-trials/kalydeco/a-study-to-evaluate-the-safety--pharmacokinetics--and-pharmacodynamics-of-ivacaftor-in-subjects-with/2021-09-24T08:13:56+00:00weekly0.7https://www.medthority.com/clinical-trials/imbruvica/combination-of-pci-32765-with-obinutuzumab-in-untreated-follicular-lymphoma--alternative-/2021-09-24T08:13:52+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--as-monotherapy-in-participants-with-advanced-hepatocellular-carcino/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/a-multicenter--double-blind--randomized-withdrawal-extension-study-of-subcutaneous-secukinumab-in-pr-1/2021-09-24T08:13:30+00:00weekly0.7https://www.medthority.com/clinical-trials/ondexxya/a-study-in-older-subject-to-evaluate-the-safety-and-ability-of-andexanet-alfa-to-reverse-the-anticoa/2021-12-16T15:16:53+00:00weekly0.7https://www.medthority.com/clinical-trials/kisqali/study-of-efficacy-and-safety-of-lee011-in-postmenopausal-women-with-advanced-breast-cancer--monalees/2024-01-25T15:01:39+00:00weekly0.7https://www.medthority.com/clinical-trials/cabometyx/cabozantinib-versus-sunitinib-for-metastatic-variant-histology-renal-cell-carcinoma/2021-09-24T08:13:25+00:00weekly0.7https://www.medthority.com/clinical-trials/herceptin/a-study-of-trastuzumab-emtansine-versus-trastuzumab-as-adjuvant-therapy-in-patients-with-her2-positi/2021-09-24T08:13:49+00:00weekly0.7https://www.medthority.com/clinical-trials/spinraza/study-of-nusinersen--biib058--in-participants-with-spinal-muscular-atrophy/2024-10-18T10:33:55+00:00weekly0.7https://www.medthority.com/clinical-trials/gazyvaro/a-multicentre--phase-iii--open-label--randomized-study-in-previously-untreated-patients-with-advance/2021-09-24T08:13:42+00:00weekly0.7https://www.medthority.com/clinical-trials/cosentyx/a-52-week--multicenter-study-to-assess-the-time-course-of-response-to-secukinumab-on-joint-inflammat/2024-03-05T13:22:01+00:00weekly0.7https://www.medthority.com/clinical-trials/vyepti/evaluation-of-ald403-eptinezumab-in-the-prevention-of-chronic-migraine-promise-2/2023-05-16T07:40:51+00:00weekly0.7https://www.medthority.com/clinical-trials/portrazza/first-line-treatment-of-participants-with-stage-iv-squamous-non-small-cell-lung-cancer-with-necitumu/2025-05-05T14:29:34+00:00weekly0.7https://www.medthority.com/clinical-trials/ilumetri/a-study-to-evaluate-the-efficacy-and-safety-tolerability-of-subcutaneous-tildrakizumab--sch-900222-m/2021-09-24T08:13:50+00:00weekly0.7https://www.medthority.com/clinical-trials/cyramza/a-study-of-ramucirumab--ly3009806--plus-docetaxel-in-participants-with-urothelial-cancer--range-/2024-03-05T12:59:30+00:00weekly0.7https://www.medthority.com/clinical-trials/ondexxya/a-study-in-older-subjects-to-evaluate-the-safety-and-ability-of-andexanet-alfa-to-reverse-the-antico/2021-12-16T15:17:16+00:00weekly0.7https://www.medthority.com/clinical-trials/fycompa/a-study-to-evaluate-efficacy-and-safety-of-perampanel-administered-as-an-adjunctive-therapy-in-pedia/2021-09-24T08:13:42+00:00weekly0.7https://www.medthority.com/clinical-trials/gazyvaro/cll11--a-study-of-obinutuzumab--ro5072759--ga101---with-chlorambucil-in-patients-with-previously-unt-1/2021-09-24T08:13:42+00:00weekly0.7https://www.medthority.com/clinical-trials/gemzar/margetuximab-plus-chemotherapy-vs-trastuzumab-plus-chemotherapy-in-the-treatment-of-her2--metastatic/2021-09-24T08:13:43+00:00weekly0.7https://www.medthority.com/clinical-trials/shingrix/study-to-evaluate-efficacy--safety-and-immunogenicity-of-gsk-biologicals--herpes-zoster--hz--vaccine/2026-01-26T15:03:58+00:00weekly0.7https://www.medthority.com/clinical-trials/hemlibra/a-study-to-evaluate-the-efficacy--safety--and-pharmacokinetics-of-prophylactic-emicizumab-versus-no-/2021-09-24T08:13:48+00:00weekly0.7https://www.medthority.com/clinical-trials/dupixent/continuation-of-traverse--lts12551-evaluating-dupilumab-safety-in-patients-with-asthma--long-term-fo/2021-09-24T08:13:34+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/acute-exacerbations-treated-with-benralizumab--the-abra-study---abra-/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-pembrolizumab--mk-3475--plus-enzalutamide-versus-placebo-plus-enzalutamide-in-participants-/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/fasenra/efficacy-and-safety-study-of-benralizumab-in-adults-and-adolescents-inadequately-controlled-on-inhal/2021-09-24T08:13:40+00:00weekly0.7https://www.medthority.com/clinical-trials/biktarvy/safety-and-efficacy-of-bictegravir-emtricitabine-tenofovir-alafenamide-versus-abacavir-dolutegravir-/2021-09-24T08:13:22+00:00weekly0.7https://www.medthority.com/clinical-trials/keytruda/study-of-lenalidomide-and-dexamethasone-with-or-without-pembrolizumab--mk-3475--in-participants-with/2021-09-24T08:13:58+00:00weekly0.7https://www.medthority.com/clinical-trials/herceptin/a-study-to-evaluate-the-efficacy-and-safety-of-atezolizumab-or-placebo-in-combination-with-neoadjuva/2021-09-24T08:13:49+00:00weekly0.7https://www.medthority.com/clinical-trials/ilumetri/a-study-of-tildrakizumab-in-pediatric-subjects-with-chronic-plaque-psoriasis/2021-09-24T08:13:50+00:00weekly0.7https://www.medthority.com/clinical-trials/tafinlar/dabrafenib-plus-trametinib-vs-vemurafenib-alone-in-unresectable-or-metastatic-braf-v600e-k-cutaneous/2024-01-30T10:52:32+00:00weekly0.7https://www.medthority.com/clinical-trials/omvoh/a-study-to-assess-if-mirikizumab-is-effective-and-safe-compared-to-secukinumab-and-placebo-in-modera/2024-03-05T13:53:59+00:00weekly0.7https://www.medthority.com/clinical-trials/invokana/evaluation-of-the-effects-of-canagliflozin-on-renal-and-cardiovascular-outcomes-in-participants-with/2021-09-24T08:13:53+00:00weekly0.7https://www.medthority.com/clinical-trials/adcetris/a-phase-3-study-of-brentuximab-vedotin--sgn-35--in-patients-at-high-risk-of-residual-hodgkin-lymphom/2024-02-27T14:02:05+00:00weekly0.7https://www.medthority.com/clinical-trials/atripla/comparison-of-mk-1439a-and-atripla--in-treatment-naive-human-immunodeficiency-virus-type-1--hiv-1--i/2024-02-27T14:45:17+00:00weekly0.7https://www.medthority.com/clinical-trials/avastin/a-study-of-atezolizumab-in-combination-with-bevacizumab-compared-with-sorafenib-in-patients-with-unt/2021-09-24T08:13:21+00:00weekly0.7